Distal end supported tissue slitting apparatus

Description

FIELD OF THE DISCLOSURE

The present disclosure relates generally to devices, methods and systems for separating tissue in a patient, and more specifically, to techniques for separating tissue attached to leads in a patient.

BACKGROUND

Cardiac pacing systems typically include a pacemaker and one or more leads, which are placed inside the body of a patient. The pacemaker includes a power source and circuitry configured to send timed electrical pulses to the lead. The lead carries the electrical pulse to the heart to initiate a heartbeat, and transmits information about the heart's electrical activity to the pacemaker. The lead can include a fixation mechanism that holds the lead to the cardiac tissue. In some cases, a lead is inserted through a vein or artery (collectively vasculature) and guided to the heart where it is attached. In other instances, a lead is attached to the outside of the heart. During its time in the body, tissue can attach to the lead in the form of lesions, adhesions or scar tissue, or tissue can encase a lead. In addition, the lead and/or tissue can become attached to the vasculature wall. At times, leads may be removed from patients for numerous reasons, including but not limited to, infections, lead age, and lead malfunction. Accordingly, removal or extraction of the lead may present associated complications.

Current lead extraction techniques include mechanical traction, mechanical devices, and laser devices. Mechanical traction can be accomplished by inserting a locking stylet into the hollow portion of the lead and then pulling the lead to remove it. An example of such a lead locking device is described and illustrated in U.S. Pat. No. 6,167,315 to Coe et al., which is hereby incorporated herein by reference in its entirety for all that it teaches and for all purposes. In some cases, dilating telescopic sheaths may also be used to strip away the scar tissue adhering the lead to the body. Examples of a such devices and methods used to extract leads is described and illustrated in United States Patent Publication No. 2008/0154293 to Taylor, which is hereby incorporated herein by reference in its entirety for all that it teaches and for all purposes.

Dilation techniques typically involve pushing tissue away from the lead when the sheath is pushed longitudinally along the lead. However, this pushing technique may be difficult to implement, particularly when the lead has a tortuous path or curvature because the requisite longitudinal forces to extract the tissue from the lead in under these circumstances increase. The longitudinal forces also may require heavy counter forces on the lead, which may result in lead breakage.

Some mechanical sheaths have proposed trigger mechanisms for extending a blade from a sheath. At least some of these devices, however, involve complicated activation mechanisms and may not be well suited for negotiating the tortuous paths that exist in certain vascular or physiological environments.

Laser devices typically employ laser energy to cut the scar tissue away from the lead thus allowing for removal. Examples of such laser devices and systems are described and illustrated in U.S. Pat. Nos. 5,383,199 and 5,824,026 and 5,916,210 and 6,228,076 and 6,290,668 all of which are hereby incorporated herein by reference in their entirety for all that they teach and for all purposes.

Further complicating lead removal is the fact that in some cases, the leads may be located in, and/or attached to, the body of a patient in a structurally-weak portion of the vasculature. For instance, typical leads in a human may pass through the innominate vein, past the superior vena cava (“SVC”), and into the right atrium of the heart. A majority of tissue growth can occur along the SVC and other locations along the innominate vein where the leads make contact with the vein walls. However, tissue growth can also occur at locations within a patient where the leads make contact with arterials or other areas of the vasculature. Certain veins and arteries, and certain areas of vein and arterial walls, can be thin which can make lead removal a complicated and delicate process.

SUMMARY

A traditional approach to removing tissue from implanted leads is based on the presumption that the tissue growths are adhered directly to the surfaces of the implanted leads. As such, methods and systems have been designed to dislocate the connection between the tissue attached to the implanted device and the body of a patient. Although some tissue may remain on the lead, current methods focus on removing most of the tissue surrounding a circumference of the lead. In other words, while tissue may remain attached around the lead, current systems essentially core around this tissue surrounding the circumference of a lead to free the lead along with a section of the cored tissue to create slack for removing the lead from a patient.

Surprisingly and unexpectedly, it has been discovered that tissue growth may not adhere directly to the implanted lead but actually form a substantially cylindrical “tube” around the implanted substantially cylindrical lead at a given contact area. Contrary to conventional wisdom, the tissue growth typically does not physically adhere to the lead. For example, this tissue growth, once formed completely around a lead, forms a tubular-shaped member that essentially holds the lead and resists lead removal. The tubular-shaped section of formed tissue around an implanted device may impart a combination of connection forces/modes that prevent the removal of the device from a patient. For example, the tubular-shaped section of formed tissue, or tissue growth, may constrict, capture, and/or surround implanted leads. In some cases, the tissue growth may constrict a lead, especially if a force is applied to one end of the lead during a removal operation. In other cases, the tissue growth may capture the lead and prevent removal, by, among other things, being attached to the patient and the lead simultaneously. Additionally or alternatively, the tissue growth, during attempted lead removal, may at least partially adhere to the lead in one or more sections while completely forming around the lead.

Based upon the surprising and unexpected discovery that tissue growth may not be directly adhered to the implanted lead, alternative devices and methods may be used to extract an object from such tissue. In other words, methods and devices are disclosed herein, that are capable of exploiting the growth nature of the tissue around a lead to efficiently extract the lead from tissue that acts to hold the lead with some type of force. The tissue growth may form around the lead such that the lead is contained from free movement within a patient. For instance, the tissue growth may impart a clamping, or constrictive, force around the circumference of the lead that can prevent movement of the lead within this constrictive tissue growth. Due to the taught and constrictive nature of the tissue around the lead, the lead may be able to be removed without mechanically removing or laser ablating the entire tissue region surrounding the lead in a 360 degree, or circumferential, fashion. Rather, initiating a cut and/or slit of the tissue along a longitudinal axis of the lead may allow a surgeon to easily separate the lead from the tissue via the slit. For example, once the tissue is initially slit, a surgeon may be able to extract the lead from the tissue, by pulling the lead with the use of a lead locking, or similar, device. This lead extraction may be made possible by the initial slit reducing the restrictive forces caused by tissue growth in a given area. Lead extraction may also be effected by moving the lead against the initial slit created to tear through the tissue growth.

The tissue growth may need to be slit or cut along an entire length of tissue growth such that the tissue growth is no longer capable of imparting clamping, or constrictive, forces around the lead. Once the tissue growth is slit along its length, removal of the lead from the section of tissue growth can be achieved using various lead removal techniques, including but not limited to, traction/counter-traction applied to the lead and growth, lead locking devices, snares, sheath insertion, moving the lead against the slit portion of the tissue, and the like.

Accordingly, there is a need for a device, method and/or system such as a device that includes a tissue slitting or cutting edge that facilitates slitting a length of formed tissue surrounding a lead, and optionally a method and system capable of removing the lead from the formed tissue that captures at least a portion of an implanted lead.

The method can include the steps of cutting only a portion of a tissue growth at least substantially surrounding an implanted object in a patient and thereafter removing the implanted object. In embodiments disclosed herein, the tissue growth may be subjected to a slitting action about a partial (i.e., not complete) periphery of an internal diameter of the tissue growth. In some embodiments, the tissue growth portion cut can be no more than about 50% of a perimeter of the tissue growth adjacent to and surrounding, substantially or completely, the implanted object at any point along an encased length of the implanted object.

The tissue slitting edge may include sharpened area, point, or blade, in a static fixed and/or dynamically deployable configuration. Additionally or alternatively, the tissue slitting edge may utilize grinding mechanisms to cause a slit in the formed tissue. Additionally or alternatively, the tissue slitting edge may utilize emitted energy, such as light, thermal energy, electromagnetic energy, and/or high-pressure fluid emission to cause a slit in the formed tissue. The tissue slitting edge can be an energy device, such as a power sheath, which typically applies a form of energy at the sheath tip to cut the scar tissue away from the lead thus allowing for removal. As the sheath is pushed over the lead and comes to an area of attachment, the operator can turn on the sheath's energy source to heat or vaporize scar tissue, forming the desired slit. One of these specialized sheaths uses electrocautery, similar to what is used to cut through tissue in surgery. Another sheath has one or more tiny lasers at its tip or edge. When activated, the lasers vaporize water molecules in scar tissue within 1 mm, forming the desired slit or cut. Additionally or alternatively, dilating telescopic sheaths or inflatable balloons having a longitudinally positioned tissue slitting edge can be expanded, thereby deploying the tissue slitting edge to form the desired slit.

Accordingly, slitting devices (e.g., in the form of knife-edges, blades, planers, lasers and other electromagnetic radiation emitters, high-pressure fluid, grinders, sanders, drills, RF devices, ultrasonic devices, and the like) can be configured in various combinations and methods by which formed tissue can be removed from an implanted lead subjected to any combination of connection modes via the formed tissue.

Removal of the formed tissue, or tissue growth, from a lead may be effected by creating a slit, or cut, along a length of the tissue growth. By slitting the formed tissue along an axial portion, or length, of the tissue connected to the surgically implanted device or surgical implant, it is anticipated that the connection to the implanted lead will be severely weakened. In many cases, the tissue slitting device may allow the implanted lead to essentially peel away from the tissue previously surrounding the implanted lead, thereby releasing it from containment. These and other needs are addressed by the various aspects, embodiments, and/or configurations of the present disclosure. Also, while the disclosure is presented in terms of exemplary embodiments, it should be appreciated that individual aspects of the disclosure can be separately claimed.

The tissue slitting device includes a flexible shaft having a proximal end, a distal end, and an internal lumen having an internal diameter configured to allow a lead, lead locking device, and/or other implanted device to pass through it. The device may also include a tissue slitting tip operatively coupled with the distal end of the flexible shaft. As can be appreciated, the slitting of formed tissue can be performed by at least one of cutting, drilling, slicing, stripping, chopping, sanding, grinding, planning, abrasion, high-pressure fluid, laser ablation, and combinations thereof. It is anticipated that the tissue slitting device may be oriented within a patient via use of the flexible shaft and monitor, or a catheter-based system. In some cases, the tissue slitting device may be positioned toward the center of the vasculature, and/or proximal to a non-traumatic leading edge, such that any sharp, or working, edge is caused to contact tissue growth and not contact the vasculature.

Among other things, the slitting section of the tissue slitting device may be biased against a lead/object via spring force. Additionally or alternatively, the tissue slitting device may include a flexible portion configured to allow the tissue slitting device to move as directed within a patient.

In has been further discovered that an efficient technique for slitting tissue growth surrounding an implanted lead involves cutting the tissue from an inner portion of the tissue growth to an outer portion of the tissue growth. The inner portion may correspond to a diameter of the tissue growth that is in contact with the lead, while the outer portion of the tissue growth may be an area adjacent to an external surface of the tissue growth, where the external surface is free from attachment to the vessel wall. This action may be similar to inserting a sharpened edge and point of a knife into a tissue growth at the internal diameter of the tissue growth and then moving the blade outwardly away from the internal diameter to cause a slit in the tissue growth. Among other things, this slitting action may place the tissue fibers under tension as the sharpened edge and point of the knife engages with and/or moves into the tissue growth in a direction away from the surface of the lead. Once the tissue is slit, the tension of the tissue fibers may be released in the slitting area. Various shapes of the slitting element may assist in the slitting action (e.g., curved, linear, compound, interrupted, serrated, sinusoidal, etc.). Additionally or alternatively, the slitting element may be configured to present a sharpened edge to the tissue, while a flat or dull edge (e.g., unsharpened) may contact the lead. This configuration of the slitting element may prevent undesired damage to the lead as the slitting element is moved along the lead and/or as the slitting element slits tissue. Although the motions of moving into the tissue growth and away from the lead may be separate, it is anticipated that such motions may be combined in a compound and/or concurrent motion.

The tissue slitting device may include an end support device disposed adjacent to the distal end of the flexible shaft. It is anticipated that the end support device may be configured to provide a clamping force to a lead within the vasculature of a patient. In one example, the clamping force may be used to grasp the lead and/or provide support for a tissue slitting element disposed adjacent to the end support element. The end support device may be arranged as one or more end support elements that are capable, alone or in combination, of restricting movement of the flexible shaft of the tissue slitting device. For example, the end support device may be arranged as a collet (e.g., a chuck, vise, spring collet, etc.) having a proximal and a distal end, with at least one tapered outer surface, and a collet lumen running from the proximal to the distal end of the end support device. As can be appreciated, the collet may be separated into two or more end support elements, that when subjected to an actuation force are configured to reduce an internal diameter of the collet lumen. A reduction in dimension of the internal diameter of the collet lumen may cause at least some of the actuation force to be applied as a clamping force around a lead or other implanted object in an area defined by the collet lumen. The actuation force may be applied by a directed force transmitted via an end support device lock that is configured to contact the tapered outer surface of the collet. The tapered outer surface of the collet can direct the actuation force toward the center of the collet. In other words, the collet may be closed (i.e., reducing the internal diameter of the collet lumen) from the end support device lock contacting the tapered outer surface of the collet.

In some embodiments, the one or more end support elements may be arranged as spring steel elements that are configured in a first position biased toward a center of the collet lumen. The bias of the spring steel elements may reduce a portion of the collet lumen internal diameter, such that the collet lumen internal diameter is less than an outer diameter associated with a lead, or implanted object. As a lead is run through the flexible shaft to the collet lumen of the tissue slitting device, the lead may force the spring steel elements into a second position away from the center of the collet lumen. In turn, the biasing force applied by the spring steel elements to the lead may cause at least a partial restriction of lead movement.

A cutting surface, or slitting element, of the tissue slitting device may be configured to move along with the end support device lock. In other words, the slitting element may be operatively connected to the end support device and/or the end support device lock. For example, a slitting element may be disposed proximal to the distal end of the end support device, and as the end support device lock engages the end support device, and/or closes an internal diameter of the collet lumen, the slitting element may move in a direction toward the distal end of the end support device. In some cases, the movement of the slitting element may be a ratio of the movement of the end support device lock (e.g., 4:1, 2:1, 1:1, 1:2, 1:4, 1:16, and/or ranges therebetween). Additionally or alternatively, the slitting element may be configured to move after a movement of the end support device and/or end support device lock. The movement of the slitting element may be caused by one or more of a pin and groove, cam profile, wedge, expanding member, and the like. As can be appreciated, such movements may be controlled as to speed, acceleration, distance, angle, dwell, return action, relative movement, etc. In one example, the end support device may be caused to close upon, and apply at least one clamping force to, a lead after which the slitting element may move. This movement can be achieved in a cam arrangement by providing a dwell for the slitting element at a first section of the cam profile. It is anticipated that various combinations and movements relative to the end support device may be used to achieve a distal end supported slitting action via the slitting element.

In addition, the slitting element may be operatively connected to, and arranged to pivot about, a pivot area to achieve a sweeping and/or arced cutting action of a cutting surface of the slitting element. In one embodiment, the sweeping cutting action may be achieved by moving the slitting element about a pivot area having at least one of a pivot point, flexure, flexure area, cantilevered member, four-bar mechanism, compound mechanism, and the like. As can be appreciated, the pivot area may be located distal to or proximal to a cutting surface of the slitting element. In some cases, the pivot area of the slitting element may be attached to the end support device, the end support device lock, and/or the flexible shaft of the tissue slitting apparatus. In any event, the slitting element is configured to provide at slit a region of the tissue growth by cutting into the tissue growth while the slitting element is supported by the end support device. For example, the tissue slitting device, or apparatus, may be presented adjacent to a tissue growth along a lead. The tissue slitting device may anchor to the lead via actuating the end support device. Once anchored, the slitting element may move toward and engage the tissue growth. As the tissue slitting element engages the tissue growth the slitting element may continue to move further into the tissue growth and/or provide an arced cutting action. Additionally or alternatively, the slitting element may wedge into an area between the lead and the tissue growth as it moves toward the tissue growth, and cut in an arced motion in a direction away from the lead toward an outside region of the tissue growth. This sweeping motion can allow the slitting element to first contact tissue at least partially surrounding a lead in an area where the tissue growth, and the tissue fibers, may be placed under tension. The tension of the fibers may be caused by the slitting element as it stretches the fibers away from the lead during its movement when in contact with the tissue. Among other things, the tension placed on the tissue growth fibers provide a taught area for the cutting surface to engage and cut along. In some embodiments, the slitting element may return along to a first position after a cutting action has been made. This action may be achieved via the one or more movement elements disclosed herein.

The phrases “at least one”, “one or more”, and “and/or” are open-ended expressions that are both conjunctive and disjunctive in operation. For example, each of the expressions “at least one of A, B and C”, “at least one of A, B, or C”, “one or more of A, B, and C”, “one or more of A, B, or C” and “A, B, and/or C” means A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B and C together. When each one of A, B, and C in the above expressions refers to an element, such as X, Y, and Z, or class of elements, such as X₁-X_n, Y1-Y_m, and Z₁-Z_o, the phrase is intended to refer to a single element selected from X, Y, and Z, a combination of elements selected from the same class (e.g., X₁and X₂) as well as a combination of elements selected from two or more classes (e.g., Y₁and Z_o).

The term “a” or “an” entity refers to one or more of that entity. As such, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the terms “comprising”, “including”, and “having” can be used interchangeably.

A “lead” is a conductive structure, typically an electrically insulated coiled wire. The electrically conductive material can be any conductive material, with metals and intermetallic alloys common. The outer sheath of insulative material is biocompatible and biostable (e.g., non-dissolving in the body) and generally includes organic materials such as polyurethane and polyimide. Lead types include, by way of non-limiting example, epicardial and endocardial leads. Leads are commonly implanted into a body percutaneously or surgically.

A “surgical implant” is a medical device manufactured to replace a missing biological structure, support, stimulate, or treat a damaged biological structure, or enhance, stimulate, or treat an existing biological structure. Medical implants are man-made devices, in contrast to a transplant, which is a transplanted biomedical tissue. In some cases implants contain electronics, including, without limitation, artificial pacemaker, defibrillator, electrodes, and cochlear implants. Some implants are bioactive, including, without limitation, subcutaneous drug delivery devices in the form of implantable pills or drug-eluting stents.

The term “means” as used herein shall be given its broadest possible interpretation in accordance with 35 U.S.C., Section 112, Paragraph 6. Accordingly, a claim incorporating the term “means” shall cover all structures, materials, or acts set forth herein, and all of the equivalents thereof. Further, the structures, materials or acts and the equivalents thereof shall include all those described in the summary of the invention, brief description of the drawings, detailed description, abstract, and claims themselves.

It should be understood that every maximum numerical limitation given throughout this disclosure is deemed to include each and every lower numerical limitation as an alternative, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this disclosure is deemed to include each and every higher numerical limitation as an alternative, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this disclosure is deemed to include each and every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

The preceding is a simplified summary of the disclosure to provide an understanding of some aspects of the disclosure. This summary is neither an extensive nor exhaustive overview of the disclosure and its various aspects, embodiments, and configurations. It is intended neither to identify key or critical elements of the disclosure nor to delineate the scope of the disclosure but to present selected concepts of the disclosure in a simplified form as an introduction to the more detailed description presented below. As will be appreciated, other aspects, embodiments, and configurations of the disclosure are possible utilizing, alone or in combination, one or more of the features set forth above or described in detail below.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are incorporated into and form a part of the specification to illustrate several examples of the present disclosure. These drawings, together with the description, explain the principles of the disclosure. The drawings simply illustrate preferred and alternative examples of how the disclosure can be made and used and are not to be construed as limiting the disclosure to only the illustrated and described examples. Further features and advantages will become apparent from the following, more detailed, description of the various aspects, embodiments, and configurations of the disclosure, as illustrated by the drawings referenced below.

FIG. 1 shows an exemplary patient vasculature in section with implanted lead and multiple locations of tissue growth in accordance with some embodiments of the present disclosure;

FIG. 2A shows a detail section view of a patient vasculature and implanted lead subjected to a traction force in a first path in accordance with some embodiments of the present disclosure;

FIG. 2B shows a detail section view of a patient vasculature and implanted lead subjected to a traction force in second path in accordance with some embodiments of the present disclosure;

FIG. 2C shows a detail section view of a patient vasculature and implanted lead subjected to a traction force in third path in accordance with some embodiments of the present disclosure;

FIG. 3 shows a section view of a curved area of vasculature with tissue growth formed around an implanted lead in accordance with embodiments of the present disclosure;

FIG. 4 shows a cross-sectional view of the curved area of vasculature of FIG. 3 taken along line A-A;

FIG. 5A shows a cross-sectional view of an area of vasculature with a tissue slitting device introduced in accordance with embodiments of the present disclosure;

FIG. 5B shows a cross-sectional view of an area of vasculature with a tissue slitting device engaging formed tissue in accordance with embodiments of the present disclosure;

FIG. 5C shows a cross-sectional view of an area of vasculature with a tissue slitting device slitting formed tissue in accordance with embodiments of the present disclosure;

FIG. 6A shows a section view of a curved area of vasculature with a tissue slitting device first introduced in accordance with embodiments of the present disclosure;

FIG. 6B shows a section view of a curved area of vasculature with a tissue slitting device in a first slitting position in accordance with embodiments of the present disclosure;

FIG. 6C shows a section view of a curved area of vasculature with a tissue slitting device in a second slitting position in accordance with embodiments of the present disclosure;

FIG. 6D shows a section view of a curved area of vasculature with a tissue slitting device in a third slitting position in accordance with embodiments of the present disclosure;

FIG. 7A shows a side view of a tissue slitting apparatus in a first position in accordance with embodiments of the present disclosure;

FIG. 7B shows a side view of a tissue slitting apparatus in a second position in accordance with embodiments of the present disclosure;

FIG. 7C shows a side view of a tissue slitting apparatus in a third position in accordance with embodiments of the present disclosure;

FIG. 8 shows an end view of a tissue slitting device inside an area of vasculature in accordance with embodiments of the present disclosure; and

FIG. 9 is a flow diagram depicting a tissue slitting method in accordance with embodiments of the present disclosure.

It should be understood that the drawings are not necessarily to scale. In certain instances, details that are not necessary for an understanding of the disclosure or that render other details difficult to perceive may have been omitted. It should be understood, of course, that the disclosure is not necessarily limited to the particular embodiments illustrated herein.

DETAILED DESCRIPTION

Before any embodiments of the disclosure are explained in detail, it is to be understood that the disclosure is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the following drawings. The disclosure is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

Embodiments of the present disclosure are directed to tissue slitting or cutting devices and methods of using tissue slitting devices to remove an implanted lead from within the vascular system of a patient. Among other things, the method of removing an implanted lead from formed tissue may include causing at least a partial separation of tissue that lies along an axial length of the implanted lead. In some embodiments, the tissue may be slit or cut along an entire length of the tissue growth to enable removal of the implanted lead. In other embodiments, the tissue may be slit or cut along a section of the tissue growth to allow an implanted lead to be removed from a patient.

While the phrases “tissue slitting edge” or “tissue cutting edge” are used in this disclosure, it is not limited to a blade or other cutting surface. These phrases are further intended to encompass any modality for slitting or cutting tissue, including the various modalities discussed herein. Nonlimiting examples include not only a sharpened area, point, or blade but also an abrasive or cutting wire or fiber, atherotomes (microsurgical blades) mounted on an inflatable (cutting) balloon, a grinder, high intensity light such as produced by a laser, thermal or infrared energy, electromagnetic energy, and/or high-pressure fluid.

FIG. 1 depicts an exemplary patient 102 with an implanted lead 104 running along the left innonimate vein 112 past the superior vena cava (“SVC”) and connected into, or about, the right ventricle of the heart 106. Along the length of the lead 104 at least one formed tissue growth 108 is shown where the tissue 108 may completely surround a section of the lead 104. In a typical lead 104 explant procedure, the one or more of the tissue growths 108 may act to contain the lead 104. For example, the tissue 108 may impart one or more forces (e.g., constrictive, shear, compression, and the like) on the lead 104 that may act to prevent successful removal of the lead 104 when subjected to a traction force 120.

FIGS. 2A-C show examples of an implanted lead 104 subjected to a traction force via different paths in a patient 102 vasculature. Accordingly, the methods and/or devices disclosed in conjunction with any of the FIGS. 2A-C may equally apply to all instances disclosed.

FIG. 2A shows a detail view of a heart 106 having an implanted lead 104 subjected to a traction force 120 in a first path in accordance with embodiments of the present disclosure. In some embodiments, a lead 104 explant procedure may involve removing the lead from a patient 102 via one or more paths. For example, a lead-locking, or other traction, device may be engaged with the lead 104 and then used to pull the lead 104 from a patient. However, in some cases the lead 104 may be contained by a formed tissue growth 108 that resists the traction force 120 applied to the lead 104. As can be appreciated, subjecting the lead 104 to excessive traction forces 120 may cause a tear inside the patient 102 where the tissue is attached to the vasculature. In one example, a tissue growth 108 may form along a critical area of the vasculature, such as the SVC curve 116, of a patient. If this critical area is torn during a lead 104 explant procedure, the result can be fatal to the patient 102.

Complicating the lead 104 removal process is the fact that the tissue growth 108 surrounding a lead 104 may attach to a vessel in a curved portion of the vasculature. Removal of the lead 104 from such a curved portion of vasculature can present a challenge when introducing tissue removal devices alone or in conjunction with traction devices. In some cases, the tissue removal devices include sharp edges, aggressive tips, or imprecise actuation mechanisms that can puncture the thin walls of a patient 102 vasculature. It is an aspect of the present disclosure to orient a tissue slitting working end adjacent to the unconnected, or tissue free, side 124 of a vessel wall. This orientation can prevent puncture and/or damage occurring to the vasculature at the tissue connected side 128 of the vessel wall.

Referring now to FIG. 2B a detail section view of a patient vasculature and implanted lead 104 subjected to a traction force 120 in second path in accordance with some embodiments of the present disclosure is shown. In some instances, at least one end of the lead 104 may be directed inside a patient 102 for removal via a path within the vasculature. Direction of the lead 104 may be effected via a snaring tool, lead-locking device, traction device, combinations thereof, and the like. As shown in FIG. 2B, the lead 104 is directed toward the general direction of a patient's femoral artery via the inferior vena cava. The lead 104 may be directed in the manner shown to provide additional tearing forces on the tissue growth 108 by the lead 104 being subjected to a traction force 120. In one embodiment, the tissue growth 108 may be at least partially slit and the tearing forces created by pulling the lead 104 along the traction force 120 line cause the lead 104 to separate from the tissue growth 108. In other embodiments, a tissue slitting device may be run along the lead 104 to the tissue growth 108 via the femoral artery.

In some embodiments, the lead 104 may be captured and pulled such that the pull force causes the lead 104 to turn inside a patient 102. This mode of capture and pulling may cause a bending at a first connection point between the tissue growth 108 and the lead 104. When the tissue slitting device is engaged with the tissue growth 108, the assistive bending force provided by the traction force 120 can aid in slitting the tissue growth 108. For instance, the bending force may cause a stretching of the tissue growth 108 where the lead engages with the tissue growth 108. This stretching of tissue may assist in the slitting operation by causing tension on the fibers of the tissue growth 108 that, when slit, pull away from the tissue slitting device engagement area. As can be expected, the slitting operation may be performed in any area within a patient that is capable of receiving a tissue slitting device.

FIG. 2C shows a detail section view of a patient vasculature and implanted lead 104 subjected to a traction force 120 in third path in accordance with some embodiments of the present disclosure. Similar to FIGS. 2A and 2B, the lead 104 may be directed along a path in the patient vasculature. In this case, the lead 104 may be directed toward the general direction of a patient's jugular vein.

As can be appreciated, the path chosen for removal of a lead 104 from a patient 102 may depend on one or more of the orientation of the lead 104 within a patient 102, the state of the at least one tissue growth 108, the lead removal device used, and the tissue slitting device used. In some cases, the lead 104 (e.g., pacing, defibrillator, etc.), or other object, may have moved after implantation. In these scenarios, the lead 104 may have to be captured via some other method. In some embodiments, a capturing tool equipped with a lasso, snare, or other lead grasping element may need to be inserted into the patient 102. As can be expected, the capturing tool may be inserted into the patient 102 via any number of the veins and/or arteries that are interconnected to the lead 104 location in the vasculature. For example, the lead 104 may be grasped via a capturing tool that has been inserted through a patient's femoral artery and led to the point of the vasculature where the lead's 104 free end may be located.

In some embodiments, rather than attach a separate mechanical traction device, the capturing tool may be used to provide traction force 120 during the tissue slitting operation. In accordance with embodiments of the present disclosure, the lead may be grasped via a capturing tool, or lead-locking device, and/or removed via some other pathway in the vasculature. In other words, the lead may be accessed via one or more veins, arteries, chambers, biological channels, and/or other sections of the vasculature of a patient 102.

FIG. 3 shows a section view of a curved area of vasculature with tissue growth 108 formed around an implanted lead 104 in accordance with embodiments of the present disclosure. The tissue growth 108 may completely surround a section of the lead 104 and even be attached to a vessel wall at a tissue connected side 128 of the vasculature. In some cases, the tissue growth 108 may not be adhered to at least one free side 124 of a vessel, such that a vessel opening 126 exists where bodily fluid may pass through the vessel unobstructed. Surprisingly and unexpectedly, it has been discovered that the tissue growth 108, before attempted lead extraction, is commonly at least substantially free of and even more commonly completely free of attachment to the lead 104.

FIG. 4 shows a cross-sectional view of the curved area of vasculature of FIG. 3 taken along line A-A. In some embodiments, reference may be made to the tissue growth 108 forming a tube 132 (or cylindrical or sock-like structure) around the implanted lead 104. Previous methods have been disclosed that are directed to separating the tissue around the lead 104 in the area defined by the tube 132. It is an aspect of the present disclosure to provide one or more methods and devices to effectively separate the tissue growth 108 along a length of the lead to release the lead 104 from the containing forces of the tissue growth 108. In some embodiments, the tissue growth 108 may be slit at a portion of the tissue growth 108 where the thickness of tissue is minimal between the lead 104 and the open area 126 of the vessel.

In embodiments disclosed herein, the tissue growth 108 may be subjected to a slitting action about a partial (i.e., not complete) periphery of an internal diameter of the tissue growth 108. Stated another way, at any selected point along the tissue growth 108 or tube 132 the amount of the adjacent tissue cut or slit 130 to free the lead 104 is commonly no more than about 50%, more commonly no more than about 25%, more commonly no more than about 10%, and even more commonly no more than about 5% of the diameter of the tissue growth 108 or tube 132. The length of the cut or slit 130 in the tissue growth 108 or tube 132 is commonly at least about 50%, more commonly at least about 75%, more commonly at least about 90%, and even more commonly at least about 95% of the total length of the portion of the lead 104 surrounded by the tissue growth 108 or tube 132 along an actual and projected line of the cut or slit.

FIGS. 5A-C show a cross-section of a vessel where a tissue slitting device 504 is progressively engaged with a tissue growth 108. As shown, the tissue slitting device causes a section of the tissue growth 108 to separate from a portion of the lead 104 allowing the forces containing the lead 104 to be severely weakened and/or eliminated.

Referring to FIG. 5A a cross-sectional view of an area of vasculature with a tissue slitting device 504 introduced therein in accordance with embodiments of the present disclosure is shown. The tissue slitting device 504 includes a tissue slitting tip 508 that is configured to separate tissue growth 108. In one embodiment, the tissue slitting tip 508 may be oriented such that a slitting operation is performed on the thinnest section of tissue growth 108 between the lead 104 and the open area 126 of the vessel. Orientation of the tissue slitting device 504 may be achieved in operation via a fluoroscopy and/or other monitoring devices and the use of one or more radiopaque markers on the tissue slitting device 504. Once the tissue slitting device 504 is oriented, the tissue slitting device 504 may contact the tissue growth 108 at an engagement area 510.

In any of the embodiments disclosed herein, the tissue slitting device may include an imaging system configured to provide an image from within the vasculature of a patient 102. It is anticipated that the imaging system may be disposed adjacent to the distal tip of the tissue slitting device. Examples of such imaging systems may include, but are in no way limited to, technology incorporating Intravascular Ultrasound (“IVUS”), Optical Coherence Tomography (“OCT”), radio imaging, magnetic tracking, three-dimensional (“3D”) imaging, and other technologies that may be used to obtain an image within a patient.

FIG. 5B shows a cross-sectional view of an area of vasculature with a tissue slitting device 504 engaging formed tissue 108 in accordance with embodiments of the present disclosure. As the tissue slitting device 504 engages the tissue growth 108 the tissue slitting device 504, may slit the tissue growth 108 by splitting, cutting, tearing, grinding, sanding, ablating, and/or otherwise causing a separation of tissue at the engagement area 510.

FIG. 5C shows a cross-sectional view of an area of vasculature with a tissue slitting device 504 slitting formed tissue 108 in accordance with embodiments of the present disclosure. As shown in FIG. 5C, the tissue growth 108 is separated along a section of the lead 104 about the engagement area 510. In some embodiments, the tissue slitting device may be subsequently removed from the tissue growth 108 by moving the lead 104 in the direction of the separated tissue.

FIGS. 6A-D show a section view of a curved area of vasculature where an embodiment of a tissue slitting device 604 is progressively engaged with a tissue growth 108. As shown, the tissue slitting device 604 causes a section of the tissue growth 108 to separate from a portion of the lead 104 allowing the forces containing the lead 104 to be severely weakened and/or eliminated.

FIG. 6A shows a section view of a curved area of vasculature with a tissue slitting device 604 first introduced in accordance with embodiments of the present disclosure. The tissue slitting device 604 is indexed into position via a directional force 618 adjacent to the tissue growth 108. The directional force 618 may be applied to the tissue slitting device 604 via one or more mechanical actuators, electrical actuators, manual positioning, and combinations thereof.

In some embodiments, the tissue slitting device 604 includes a flexible shaft having a proximal end, a distal end 612, and an internal lumen 616 having an internal diameter configured to allow a lead, lead locking device, and/or other implanted device to pass through it. The device may also include a tissue slitting tip 608 operatively attached to the distal end 612 of the flexible shaft. As can be appreciated, the slitting of formed tissue can be performed by at least one of cutting, drilling, slicing, stripping, chopping, sanding, grinding, planning, abrasion, high-pressure fluid, laser ablation, and combinations thereof. In one embodiment, the tissue slitting tip 608 of the tissue slitting device 604 may be described in conjunction with the tissue slitting apparatus 704 of FIGS. 7A-9. For example, the tissue slitting tip 608 may correspond to the slitting element 716 of the tissue slitting apparatus 704. It is anticipated that the tissue slitting device 604 may be oriented within a patient via use of the flexible shaft and monitor, or a catheter-based system. In some cases, the tissue slitting device 604 may be positioned toward the center of the vasculature, and/or proximal to a non-traumatic leading edge, such that any sharp, or working, edge is caused to contact tissue growth 108 and not contact the vasculature (e.g., the tissue connected side 128 wall and the free side 124 wall of a vessel).

Additionally or alternatively, the tissue slitting tip 608 and effective slitting section of the tissue slitting device 604 may be biased against a lead 104 via spring force. In some embodiments, the tissue slitting device 604 may include a flexible portion configured to allow the tissue slitting device 604 to move as directed within a patient.

FIG. 6B shows a section view of a curved area of vasculature with a tissue slitting device 604 in a first slitting position in accordance with embodiments of the present disclosure. As the tissue slitting device 604 is directed into the tissue growth 108, the tissue slitting tip 608 causes the tissue growth 108 to separate along the engagement area 610. The separated tissue 614 allows the tissue slitting device 604 to be further engaged with the tissue growth 108. Additionally or alternatively, the separated tissue 604, by releasing forces containing the lead, can allow the lead 104 to be moved about the area of the tissue slitting tip 608.

FIG. 6C shows a section of a curved area of vasculature with the tissue slitting device 604 in a second slitting position in accordance with embodiments of the present disclosure. As the tissue slitting device 604 is indexed in a direction 618 into the tissue growth 108 the tissue slitting device 604 separates tissue along an axial length of at least one side of the lead 104. In some embodiments, the lead 104 may be subjected to a traction force 120 that may be opposite to the index direction 618 of the tissue slitting device 604. This applied traction force 120 may assist in pulling the lead 104 away from the tissue growth 108 as the lead 104 is separated from containing tissue growth 108.

FIG. 6D shows a section view of a curved area of vasculature with a tissue slitting device 604 in a third slitting position in accordance with embodiments of the present disclosure. In general, the tissue slitting device 604 is indexed further into the tissue growth 108 such that the tissue growth 108 is almost completely separated from the lead 104 along a length of the tissue growth 108. In some embodiments, slitting at least a portion of the tissue growth 108 may allow the lead 104 to be removed in an explant procedure. For instance, the lead 104 may be subjected to a traction force 120 to pull the lead 104 away from any remaining the tissue growth 108. Additionally or alternatively, the lead 104 may be pulled against the remaining tissue growth 108 that surrounds the lead 104. In other embodiments, the tissue slitting device 604 may be indexed along the entire length of the tissue growth 108 to completely separate the tissue growth 108 from encapsulating, or surrounding, the lead 104.

FIGS. 7-9 are directed to embodiments of a tissue slitting device that include one or more cutting features that are configured to cut at least a portion of a tissue growth 108 along a lead 104 implanted in a patient 102. It should be appreciated that at least one portion of the descriptions accompanying each of the aforementioned figures, namely FIGS. 1-6D, may be used to describe one or more of the features (e.g., methods, systems, tissue slitting devices, components, problems, solutions, arrangements, and the like) associated with the ensuing description. Additionally or alternatively, the ensuing description may apply to one or more features of FIGS. 1-6D.

In any of the embodiments disclosed herein the cutting surface may be guarded by a mechanical sheath. A mechanical sheath may include at least one surface that acts to guard and/or protect a cutting surface from being accidentally exposed to one or more sensitive areas of the vasculature during navigation of a tissue slitting device within a patient 102. In one embodiment, a mechanical sheath may at least partially shroud a portion of a cutting surface with a compliant material (e.g., silicone, polyurethane, rubber, polymer, combinations thereof, and the like). It is anticipated that the compliant material may be compressed when subjected to an operation force. The compression of the compliant material may subsequently expose the cutting surface of the tissue slitting device.

In another embodiment, the mechanical sheath may include a non-compliant material (e.g., metal, carbon fiber, plastic, resin, combinations thereof, and the like) that is configured to at least partially shroud a portion of a cutting surface. The non-compliant material mechanical sheath may be configured to at least partially shroud the cutting surface via a compliant member (e.g., spring, flexure, compliant material, combinations thereof, etc.) in connection with the non-compliant member that maintains a shrouded position of the non-compliant material mechanical sheath. Upon subjecting the non-compliant material mechanical sheath to an operational force, the operational force may be directed to the compliant member, which subsequently exposes the cutting surface from the mechanical sheath.

Referring now to FIG. 7A, a tissue slitting apparatus 704 is shown in a first position in accordance with embodiments of the present disclosure. In some embodiments, the tissue slitting apparatus 704 comprises a flexible shaft 708, an inner lumen 712, at least one slitting element 716 having at least one cutting surface 718, a pivot area 720, a mechanical sheath 724, an end support device 728, an end support device lock 732, and an actuation guide arrangement 736. In some embodiments, the tissue slitting apparatus may include an actuation element 710. The inner lumen 712 can be disposed between the proximal and distal end of the tissue slitting device 704, and may include a lumen of the flexible shaft 708 and/or the end support device 728 (e.g., a collet lumen). In some embodiments, the inner lumen 712 may be configured to allow a lead 104 and/or other objects to pass therethrough (e.g., a lead-locking device, traction device, snare tool, etc). As can be appreciated, the tissue slitting apparatus 704 may be indexed and/or guided along the lead 104 via the inner lumen 712 of the apparatus 704.

The tissue slitting apparatus 704 may be configured to engage with the tissue growth 108 in a patient 102 at a distal tip of the apparatus 704. In some embodiments, the distal tip of the apparatus 704 may be equipped with a slitting element 716 configured to cut the tissue growth 108. Additionally, the slitting element 716 may be configured to part the tissue as it cuts. As the slitting element 716 is moved into the tissue growth 108, the cutting surface 718 of the slitting element 716 may sever the tissue while simultaneously parting it along at least one side of the cutting surface 718.

In any of the embodiments disclosed herein, disposition of the slitting element 716 of the tissue slitting apparatus 704 may be arranged as one or more shapes, angles, and dimensions. In one embodiment, the slitting element 716 may be arranged at an angle ranging from 10 to 50 degrees from a plane that is coincident with at least two points on an axis running along the lumen 712 of the tissue slitting device 704. As can be appreciated, the slitting element 716 cutting surface 718 of the tissue slitting apparatus 704 may be defined by its axial length from the distal end of the apparatus 704. In one embodiment, the axial length of the cutting surface 718 of the slitting element 716 may range from 0.025″ to 1.500″. In another embodiment, the axial length of the cutting surface 718 of the slitting element 716 may range from 0.050″ to 0.750″.

In some embodiments, the end support device 728 may be configured to provide a clamping force to a lead 104 within the vasculature of a patient 102. In one example, the clamping force may be used to grasp the lead 104 and/or provide support for the slitting element 716 disposed adjacent to the end support device 728. Among other things, the end support device 728 can allow the slitting element 716 to slit tissue, while at least some of the forces provided by the slitting element 716 engaging and/or slitting tissue are at least partially supported at the distal end of the tissue slitting apparatus 704. The end support device 728 may be arranged as one or more end support elements 740 that are capable, alone or in combination, of restricting movement of the flexible shaft 708 of the tissue slitting apparatus 704. In some embodiments, the end support device 728 may include a proximal and a distal end. As can be appreciated, the end support device 728 may be attached to the distal end of a flexible shaft 708. In one embodiment, the proximal end of the end support device 728 may be attached to the distal end of the flexible shaft 708.

In some embodiments, the end support device 728 may be arranged as a collet (e.g., a chuck, vise, spring collet, etc.) having a proximal and a distal end, with at least one tapered outer surface 748, and a collet lumen 744 running from the proximal to the distal end of the end support device 728. In one embodiment, the collet lumen 744 may be coincident and/or coaxial with the inner lumen 712 of the apparatus 704. As can be appreciated, the end support device 728 may be separated into two or more end support elements 740 that, when subjected to an actuation force, are configured to reduce an internal diameter of the collet lumen 744. A reduction in dimension of the internal diameter of the collet lumen 744 may cause at least some of the actuation force to be applied as a clamping force around a lead 104 or other implanted object in an area defined by the collet lumen 144. The actuation force may be applied by a directed force transmitted via an end support device lock 732 that is configured to contact the tapered outer surface 748 of the end support device 728. The tapered outer surface 748 of the end support device 728 can direct the actuation force toward the center, and/or collet lumen 744, of the end support device 728. In other words, the end support device 728 may be closed (i.e., reducing the internal diameter of the collet lumen 744) from the end support device lock 732 contacting the tapered outer surface 748 of the end support device 728.

FIG. 7A shows the end support device 728 and end support device lock 732 of a tissue slitting apparatus 704 in an open condition in accordance with embodiments of the present disclosure. In other words, each of the end support elements 740 of the end support device 728 are shown in a first position (i.e., open) with an end support device lock 732 in an open state. As provided above, the end support device 728 may be arranged as a collet (e.g., a chuck, vise, spring collet, etc.) having a proximal and a distal end, with at least one tapered outer surface 748, and a collet lumen 744 running from the proximal to the distal end of the end support device 728. In some embodiments, the collet lumen 744 may be concentric with and/or coincident with an inner lumen 712 of the flexible shaft 708. It is anticipated that the collet lumen 744 may include an internal diameter sized to allow a lead 104 to pass therethrough, where the internal diameter of the collet lumen 744 is greater than an outer diameter of the lead 104 when the collet lumen 744 is in an open state.

Additionally or alternatively, the slitting element 716 may be operatively connected to, and arranged to pivot about, a pivot area 720 to achieve a sweeping and/or arced cutting action of a cutting surface 718 of the slitting element 716. In one embodiment, the sweeping cutting action may be achieved by moving the slitting element 716 about a pivot area 720 having at least one of a pivot point, flexure, flexure area, cantilevered member, four-bar mechanism, compound mechanism, and the like. As can be appreciated, the pivot area 720 may be located distal to or proximal to a cutting surface 718 of the slitting element 716. In some cases, the pivot area 720 of the slitting element 716 may be attached to the end support device 728, the end support device lock 732, and/or the flexible shaft 708 of the tissue slitting apparatus 704. In any event, the slitting element 716 is configured to provide at slit a region of the tissue growth 108 by cutting into the tissue growth 108 while the slitting element 716 is supported by the end support device 728.

It is anticipated that the slitting element 716 may be configured as a blade positioned perpendicular to the outer circumferential surface of the lead 104. The blade, or cutting surface 718, of the slitting element 716 may be configured to move along with the end support device lock 732. In other words, the slitting element 716 may be operatively connected to the end support device 728 and/or the end support device lock 732. For example, the slitting element 716 may be disposed proximal to the distal end of the end support device 728, and as the end support device lock 732 engages the end support device 728, and/or closes an internal diameter of the collet lumen 744, the slitting element 716 may move in a direction toward the distal end of the end support device 728. In some cases, the movement of the slitting element 716 may be a ratio of the movement of the end support device lock 732 (e.g., 4:1, 2:1, 1:1, 1:2, 1:4, 1:16, and/or ranges therebetween). Additionally or alternatively, the slitting element 716 may be configured to move after a movement of the end support device 728 and/or end support device lock 732.

In some embodiments, the slitting element 716 may be caused to contact the lead 104 at a circumferential surface of the lead 104 before the slitting element 716 performs a cutting action. Among other things, contact with the lead 104 may allow the slitting element 716 to cut the tissue growth 108 from a lead surface outwardly toward an open area 126 of the vessel. In other words, the circumferential surface of the lead 104 may act as a cutting reference point for the slitting element 716 to base from, and/or return to, during a progressive cutting operation.

Additionally, the slitting element 716 may be equipped with a wedge to peel the tissue away as it is being cut by the cutting surface 718 of the slitting element 716. Additionally or alternatively, the angle of the cutting surface 718, or blade, relative to the axis, and/or outer circumferential surface, of the lead 104 may be configured to achieve an adequate cutting angle in the tissue growth 108, such that the tissue 108 is slit in a manner to best achieve lead 104 removal. That is, due to the overall size of the lumen 712, a small angle itself may create a sharp leading edge sufficient to cut and slit the tissue growth 108. The angle may also create smooth translation and slitting of the remainder of the tissue as the tissue slitting apparatus 704 traverses longitudinally along a direction of the lead 104.

FIG. 7B shows a side view of a tissue slitting apparatus in a second position in accordance with embodiments of the present disclosure. For example, the tissue slitting device 704, or apparatus, may be presented adjacent to a tissue growth 108 along a lead 104. The tissue slitting apparatus 704 may anchor to the lead 104 via an actuation of the end support device 728. Once anchored, or as the apparatus is being anchored, the slitting element 716 may move toward, and even engage, a tissue growth 108. The movement of the slitting element 716 may be caused by one or more of a pin and groove, cam profile, wedge, expanding member, and the like. For example, an end support device lock 732 may be moved in a first direction 752, which can engender an actuation of an end support device 728 and a corresponding movement of a slitting element 716. In part, the movement of the slitting element 716 may be achieved by the slitting element 716 being operatively connected to the end support device 728 and/or the end support device lock 732. The movement of the slitting element 716 in the first direction 752 may expose a cutting surface 718 of the slitting element 716 from a mechanical sheath 724. As can be appreciated, such movements may be controlled as to speed, acceleration, distance, angle, dwell, return action, relative movement, etc. In one example, the end support device 728 may be caused to close upon, and apply at least one clamping force to, a lead 104 after which the slitting element 716 may move. This movement can be achieved in a cam arrangement by providing a dwell for the slitting element 716 at a first section of the cam profile. It is anticipated that various combinations and movements relative to the end support device 728 may be used to achieve a distal end supported slitting action via the slitting element 716.

FIG. 7B shows the end support device 728 and end support device lock 732 of a tissue slitting apparatus 704 in a closed condition in accordance with embodiments of the present disclosure. In some embodiments, the end support device lock 732 may be actuated via an actuation element 710 to move in a first direction 752 toward the distal end of the apparatus 704. As the end support device lock 732 is subjected to the actuation force the internal diameter of the collet lumen 744 may be reduced. For example, each of the one or more end support elements 740 may be moved toward the collet lumen as shown in FIG. 7B. A reduction in dimension of the internal diameter of the collet lumen 744 may cause at least some of the actuation force to be applied as a clamping force around a lead 104 or other implanted object in an area defined by the collet lumen 744. This force may anchor the distal end of the tissue slitting apparatus 704 to the lead 104. As disclosed herein, the actuation force may be applied by a directed force transmitted via an actuation element 710 to an end support device lock 732 that may be configured to contact the tapered outer surface 748 of the end support device 728. The tapered outer surface 748 of the end support device 728 can direct the actuation force toward the center of the collet lumen 744. In other words, the end support device 728 may be closed (e.g., by reducing the internal diameter of the collet lumen 744) from the end support device lock 732 contacting the tapered outer surface 748 of the end support device 728.

FIG. 7C shows a side view of a tissue slitting apparatus 704 in a third position in accordance with embodiments of the present disclosure. As shown, the tissue slitting element 716 being moved toward the distal end of the apparatus 704 (e.g., in the first direction 752 described in conjunction with FIG. 7B) may continue to move to a further distal position (e.g., further into a tissue growth 108) and/or provide an arced, or lifted, cutting action (e.g., over a section of the engaged tissue growth 108) shown by lift direction 756. Additionally or alternatively, the slitting element 716 may wedge into an area between the lead 104 and a tissue growth 108 as it moves toward a tissue growth 108, and cut in an arced, or lifted, motion in lift direction 756, away from the lead 104 toward an outside region of a tissue growth 126. This sweeping motion, shown by lift direction 756, can allow the slitting element 716 to first contact tissue at least partially surrounding a lead 104 in an area where the tissue growth 108, and the tissue fibers, may be placed under tension. The tension of the fibers may be caused by the slitting element 716 as it stretches the fibers away from the lead 104 during its movement when in contact with the tissue. Among other things, the tension placed on the tissue growth 108 fibers can provide a taught area for the cutting surface 718 of the slitting element 716 to engage and cut along. In some embodiments, the slitting element 716 may return to a first position (e.g., in contact with the lead 104, adjacent to the lead 104, and/or in a neutral position, etc.) after a cutting action has been made. This action may be achieved via the one or more movement elements (e.g., the actuation element 710, end support device 728, end support device lock 732, actuation guide arrangement 736, etc., and combinations thereof) as disclosed herein.

Additionally, embodiments of the tissue slitting apparatus disclosed herein may include at least one fluorescing material or marker (e.g., radiopaque band, marker, and the like). In some embodiments, the radiopaque marker may be arranged about and/or adjacent to a slitting element of the tissue slitting apparatus. The radiopaque marker, may assist in identifying a location of the slitting element 716 via a monitoring device. Examples of radiopaque markers may include, but are in no way limited to, materials and/or particles containing tantalum, tungsten, carbide, iridium, bismuth oxide, barium sulfate, cobalt, platinum and/or alloys and combinations thereof. In some embodiments, the inner lumen 712 may be configured to allow a lead 104 and/or other objects to pass therethrough (e.g., a lead-locking device, traction device, snare tool, etc). As can be appreciated, the tissue slitting apparatus 704 may be indexed and/or guided along the lead 104 via the inner lumen of the apparatus 704.

FIG. 8 shows an end view of a tissue slitting apparatus 704 inside an area of vasculature in accordance with embodiments of the present disclosure. In some embodiments, a slitting element 716 is oriented at least partially within the vasculature of a patient 102, which may allow the apparatus 704 to be routed through the vasculature without presenting sharp edges, cutting surfaces 718, or slitting elements 716 toward sensitive areas. The slitting element 716 oriented within the vasculature may allow the cutting surface 718 of slitting element 716 to be biased away from the vessel wall of a patient's vasculature. In other words, the tissue slitting element 716 may be oriented toward the tissue growth 108 in connection with the lead 104. A slitting orientation control feature 804 may be operatively attached to the tissue slitting apparatus 704 at, or adjacent to, the distal end of the apparatus 704. The slitting orientation control feature 804 may act to safely orient the slitting element 716 within a patient 102. In one embodiment, the slitting orientation control feature 804 may be connected to the mechanical sheath 724. It is anticipated that the slitting orientation control feature 804 may be arranged in a known relation to a slitting element 716. For instance, the slitting element 716 may be positioned at a dimension from a vessel wall contact edge or surface of the slitting orientation control feature 804, such that the dimension prevents the slitting element 716 from contacting a vessel wall 124, 128. As can be appreciated, the slitting orientation control feature 804 may prevent full 360 degree rotation of the tissue slitting apparatus 704 within a section of the vasculature of a patient 102. In one example, a tissue slitting apparatus 704 may be directed inside a patient 102 toward a tissue growth 108. As the apparatus 704 engages the tissue growth 108, any unwanted, or dangerous, rotation of the apparatus 704 that may present the slitting element 716 to a vessel wall 124, 128 can be prevented by the slitting orientation control feature 804 first contacting the vessel wall 124, 128. Such contact can prevent further rotation of the apparatus 704 and the slitting element 716 in a direction toward the vessel wall 124, 128 in contact with the slitting orientation control feature 804. Additionally or alternatively, the apparatus 704 may be allowed to rotate away from the vessel wall 124, 128 such that the slitting orientation control feature 804 moves toward the open area 126 (and safe section) of the vessel.

In accordance with embodiments of the present disclosure, the slitting element 716 may be advanced into the tissue growth 108. This advancement may be continuous or periodic. Additionally or alternatively, the slitting element 716 may be actuated in a direction toward and away from the tissue such that the slitting element 716 is presented to an area of the tissue growth 108, removed from the area, and re-presented to an area of the tissue growth 108 to successively cut the tissue growth 108 over a number of movements. For example, the tissue growth 108 can be cut in a similar manner to that of an axe chopping at a tree or of scissors cutting material. In any embodiment disclosed herein, fraction force may be applied to the lead 104 during the cutting of the tissue growth 108. Among other things, traction force 120 can prevent tears, punctures, and/or other catastrophic failures caused by the force exerted on the tissue growth 108 and/or adjacent vasculature by the tissue slitting apparatus 704.

It is anticipated that the slitting element 716 may be manufactured from a material with a suitable hardness for slitting tissue. In some embodiments, the slitting element 716 may be manufactured from a polymeric material with a durometer configured to cut a patient's tissue. Examples of polymeric material may include, but are not limited to, plastics, silicone, polytetrafluoroethylene (“PTFE”), polyethylene, polyurethane, polycarbonate, polypropylene, polyvinyl chloride (“PVC”), polystyrene, acetal, polyacetal, acetal resin, polyformaldehyde, and the like. In one embodiment, the slitting element 716 may be constructed from a crystalline or amorphous metal alloy. The slitting element 716 may comprise at least a portion of the distal tip of the tissue slitting apparatus 704. As can be appreciated, the slitting element 716 may comprise a metal insert. Examples of slitting element 716 metals may include, but are not limited to, steel, stainless steel (e.g., austenitic type 304, 316, martensitic type 420, 17-4, etc.), aluminum, titanium, tungsten carbide, silver, platinum, copper, and combinations thereof. In one embodiment, the metal may be hardened to, among other things, maintain a sharp edge during the tissue slitting process.

Additionally or alternatively, the slitting element 716 or cutting surface 718 may be removably attached to the distal tip of the tissue slitting apparatus 704. Benefits of a removably attached slitting element 716 allow for quick replacement of cutting surfaces 718 during lead removal procedures. As can be appreciated, the replacement of the cutting surface 718 may be initiated upon detecting that the cutting surface 718 of the slitting element 716 is dulling. In some cases the cutting surface 718 may be replaced with a different style of blade. The style of blade may be configured to suit a number of desires, including but not limited to, navigating difficult areas in a patient (e.g., using a curved blade, etc.), cutting difficult, dense, and/or hard tissue (e.g., using a serrated blade, a hardened blade, and combinations thereof, etc.), cutting tissue in confined and/or low-growth areas (e.g., using a miniature blade), and even removing the blade completely (e.g., using the tissue slitting device as a counter-traction sheath, etc.).

In some embodiments, the tissue slitting apparatus 704 disclosed herein may include at least one non-traumatic leading edge disposed at the most distal end of the apparatus 704. The non-traumatic leading edge may include a distal end and a proximal end. Non-traumatic surfaces on the leading edge of the device may include but are not limited to, spheroidal, ball-nose, radiused, smooth, round, and/or other shapes having a reduced number of sharp edges. These non-traumatic surfaces may be configured to prevent accidental puncture or harmful contact with the patient 102. The non-traumatic leading edge may be configured to include a tapered and/or a wedge-shaped portion. In some cases the cross-sectional area of the tapered portion increases along a length of the non-traumatic leading edge from the distal end to the proximal end of the leading edge. A knife-edge and/or cutting surface 718 may be disposed proximal to the non-traumatic leading edge of the tissue slitting apparatus 704.

The non-traumatic leading edge may be positioned to insert into an area between the tissue growth 108 and the implanted lead 104. In some cases the tapered geometry and the arrangement of the tissue slitting apparatus 704 tip may allow the most distal portion of the non-traumatic leading edge to bias against the lead 104 and wedge under any surrounding tissue growth 108. As the non-traumatic leading edge is indexed further into the tissue growth 108, the tissue growth 108 is caused to stretch and pull away from the lead 104. Once the non-traumatic leading edge is engaged with the tissue growth 108, the cutting surface 718 of the tissue slitting apparatus 704 may be caused to slit the tissue along a length of the tissue growth 108. As can be appreciated, the slitting element 716 may include, but is not limited to, one or more cutting surfaces 718 and tissue slitting apparatus 704 disclosed herein.

Referring to FIG. 9, a tissue slitting method 900 will be described in accordance with at least some embodiments of the present disclosure. The method 900 begins at step 904 and proceeds by optionally connecting a lead-locking device or other traction device to a lead 104 (step 908). In some embodiments, the lead-locking device may be inserted into the core of an implanted lead 104. In other embodiments, a traction device may be connected to the lead 104 to provide traction on the lead 104. For instance, mechanical traction can be achieved in leads 104 by inserting a locking stylet into the lead 104 and applying a pull force onto the lead 104 via the locking stylet.

Once a traction device is attached to the lead 104, the method 900 continues by feeding the fraction device and/or the lead 104 through the internal, or inner, lumen 712 of the tissue slitting apparatus 704 (step 912). In some embodiments, a lead-locking device may be optionally used. In one embodiment, the lead 104 itself may be threaded through the inner lumen 712 of the tissue slitting apparatus 704. In any event, the lead 104 and/or the lead-locking device may be threaded through a lumen 712 associated with the tissue slitting apparatus 704. For example, the lead-locking device may be inserted through the lumen in an implanted lead 104 and attached to the internal portions of the implanted lead 104, which can be at the distal portion or proximal to the distal portion of the lead 104. The tissue slitting apparatus 704 may be part of a catheter that rides over the external portion of the lead 104 and lead-locking device and is configured to remove tissue along an axial length of the tissue 108 in contact with the lead 104.

As the tissue slitting apparatus 704 is engaged with the lead 104, a slight fraction force may be applied to the lead 104 to allow the tissue slitting apparatus 704 to guide along the lead 104. The tissue slitting apparatus 704 can be moved toward the first formed tissue growth 108 while applying a mechanical fraction force to the lead 104 itself, through a locking stylet, and/or other traction device. Mechanical traction force may be applied with appropriate force to prevent tearing the vein or artery (e.g., vessel) wall by moving the lead 104 and tissue before they are separated. In some embodiments, the tissue slitting apparatus 704 may be observed moving inside a patient 102 via a fluoroscope or other monitor. It is anticipated that the distal tip, or some other area, of the tissue slitting apparatus 704 may include a fluorescing material or marker (e.g., radiopaque band, etc., and the like as previously described). This fluorescing material or marker may be used to aid in monitoring the movement of the tissue slitting apparatus 704 when it is inside a patient 102.

Next, the method 900 continues by moving the tissue slitting apparatus 704 into contact with the formed tissue growth 108 (step 916). For example, the tissue slitting apparatus 704 may be advanced until resistance of movement along the lead 104 is detected. In one embodiment, the location of the tissue slitting apparatus may be determined using one or more imaging modality (e.g., IVUS, OCT, 3D, and others as disclosed herein, etc.). In some embodiments, the slitting element 716 of the tissue slitting apparatus 704 may be oriented toward the center of the vessel, or away from the vessel wall 124, 128 connecting the lead 104 to the vessel. In addition to preventing accidental puncture, trauma, or other damage to the delicate surfaces of the vasculature this orientation of the tissue slitting apparatus 704 may aid in the slitting and peeling away of the tissue 108 from the implanted lead 104. While applying mechanical traction force, the leading portion (of the tissue slitting apparatus 704) may include a slitting element 716 having a sharp cutting surface 718, which may be configured to cut into the tissue growth 108. As the tissue slitting apparatus 704 traverses along the lead 104, the slitting element 716 of the tissue slitting apparatus 704 may be configured to continue to separate the formed tissue 108. Additionally the slitting element 716, which may include an angle and/or tapered portion, can act to cause a stretching of the formed tissue growth 108 at the point where it engages with the tissue slitting element 716. This stretching of tissue may assist in the slitting operation by causing tension on the fibers of the tissue growth 108 that, when slit, pull back (or away) from the tissue slitting apparatus 704 engagement area.

The method 900 continues by retracting the tissue slitting apparatus 704 from a forced contact with the tissue growth 108 (step 920). In some embodiments, refracting the tissue slitting apparatus 704 may include using the imaging modality to position the tissue slitting apparatus 704 relative to the tissue growth 108. For example, once the tissue slitting apparatus 704 meets a tissue growth 108, the apparatus 704 may be slightly refracted from intimate contact with the tissue growth 108. In one embodiment, a retraction of the tissue slitting apparatus 704 may not be required to perform the method 900 provided herein.

Next, the method 900 continues by actuating the end support device lock 732, such that the end support device 728 locks onto the lead 104 (step 924). In some embodiments, locking the end support device 728 may prevent further movement of the tissue slitting apparatus 704 along the lead 104. Additionally or alternatively, the end support device lock 732 can provide support for the slitting element 716 at the distal end of the tissue slitting apparatus 704. In one embodiment, the end support device lock 732 may be actuated via a mechanical force applied from an actuation element 710. The mechanical force may be at least one of a linear translation, rotational translation, electromotive force, cam movement, and the like. As can be appreciated, the actuation force may be applied to the actuation element 710 such that the actuation force translates into a movement of the end support device lock 732. In some embodiments, the end support device lock 732 may move along an actuation guide track and/or a tapered outer surface 748 of the end support device 728. This move along the tapered outer surface 748 of the end support device 728 may cause one or more end support elements 740 to close, or reduce a collet lumen 744 diameter, such that the end support device 728 locks onto the lead 104.

The method 900 continues by actuating the slitting element 716 of the tissue slitting apparatus 704 (step 928). As the slitting element 716 is actuated, the cutting surface 718 of the slitting element 716 may be exposed from a sheathed position. For instance, the actuation of the slitting element 716 may move the cutting surface 718 from a position within the mechanical sheath 724 of the tissue slitting apparatus 704. One example of an actuation element 710 may include a shaft operatively connected to the slitting element 716. In this example, an actuation force may be applied to the actuation element 710 such that the actuation force translates into a movement of the slitting element 716. The actuation force can be at least one of a linear translation, rotational translation, electromotive force, cam movement, and the like.

Additionally or alternatively, the movement of the slitting element 716 may include one or more paths. For instance, a cam profile (e.g., a groove and pin, a cam surface and a cam follower, etc.) may be employed such that the slitting element 716 can make one or more of linear, arced, sweeping, lifting, and other movements. In some embodiments, the actuation of the slitting element 716 and the end support device lock 732 may be performed by a single actuator and/or actuation force.

In any event, it is anticipated that the slitting element 716 may introduce a cutting surface 718 to the tissue growth 108 at a point where the tissue growth 108 meets a lead 104, or other implanted object. As the cutting surface 718 moves into the tissue the slitting element 716 may lift in a direction away from the lead 104. This movement can cause the cutting surface 718 to cut the tissue. In some embodiments, and because the end support device 728 has locked onto the lead 104 at the distal end of the tissue slitting apparatus 704, the slitting element 716 may make sequential and/or sweeping cuts into the tissue growth 108 to create the slit as described herein. Among other things, the lifting motion of the slitting element 716 and cutting surface 718 can place the fibers of the tissue growth 108 under tension while the cutting surface 718 cuts the tissue of the tissue growth 108. As can be appreciated, supporting the slitting element 716 via locking the end support device 728 can allow for greater cutting forces to be applied via the slitting element 716. Once the slitting element 716 has performed the cutting operation, the slitting element 716 may return to its original position such that the cutting surface 718 is sheathed.

The method 900 continues when the tissue slitting apparatus 704 has completed the cutting operation (step 932). At this point, the end support device lock 732 may be unlocked (step 934). For instance, the steps of actuating the end support device lock 732, as described above, may be performed in reverse. In one embodiment, the end support device lock 732 may be actuated via a mechanical force applied from an actuation element 710. In some embodiments, the end support device lock 732 may move along an actuation guide track and/or a tapered outer surface 748 of the end support device 728 in a direction that may cause one or more end support elements 740 to open, or increase a collet lumen 744 diameter, such that the end support device 728 is released from a locked position. This unlocked end support device 728 can allow the tissue slitting apparatus 704 to move along the lead 104.

In the event that the tissue growth 108 is still restricting a movement of the lead 104, the steps above may be repeated with the tissue growth 108 or other tissue growths found along the length of the lead 104 (step 936). Once the lead 104 has been released from the restrictive forces of tissue growth, the method 900 may continue by removing the lead 104 through the inner lumen 712 of the tissue slitting apparatus 704 (step 940). The method ends at step 944.

In some embodiments, the tissue slitting apparatus 704 may be indexed forward (into the tissue formation 108) continuously or periodically. In other embodiments, the tissue slitting apparatus 704 may be repeatedly indexed into and removed from the engagement area of the formed tissue growth 108. It is anticipated that each time the tissue slitting apparatus 704 is indexed into the engagement area the device 704 can make a successively longer slit in the formed tissue growth 108. Actuation may be achieved via an actuator that is operatively connected to the actuation element 710. The actuator may be an electrical motor that is located at the proximal end of the flexible shaft 708. In some embodiments, the actuator may be manually operated via a mechanical movement at the proximal end of the flexible shaft 708 through the actuation element 710 connected to the slitting element 716. In any event, energy from the actuator may be transferred to at least one of the end support device lock 732, end support device 728, and the slitting element 716 via one or more of a shaft, rod, cam, bar, pin, link, groove, combinations thereof, and the like that are configured to transmit force from the proximal end of the tissue slitting apparatus 704 to the at least one of the end support device lock 732, end support device 728, and the slitting element 716.

As described above, the method may be continued by determining whether other tissue growths exist, and if so, indexing the tissue slitting apparatus 704 through each formed tissue growth 108 that is surrounding a section of the implanted lead 104 in the vasculature. Once all of the formed tissue growths 108 are slit, or separated, the tissue slitting apparatus 704 may be removed from the patient 102. Additionally or alternatively, once the slits have been made the lead 104 may be removed by applying a pull force to the lead-locking device in the same direction as the mechanical traction force previously applied to the lead 104. It is anticipated that any movement of the tissue slitting apparatus 704 may be accompanied by an applied mechanical traction force to the lead/lead-locking device.

In the appended figures, similar components and/or features may have the same reference label. Further, various components of the same type may be distinguished by following the reference label by a letter that distinguishes among the similar components. If only the first reference label is used in the specification, the description is applicable to any one of the similar components having the same first reference label irrespective of the second reference label.

Presented herein are embodiments of a tissue separating device, system, and method. As described herein, the device(s) may be electrical, mechanical, electro-mechanical, and/or combinations thereof.

Also, while the flowcharts have been discussed and illustrated in relation to a particular sequence of events, it should be appreciated that changes, additions, and omissions to this sequence can occur without materially affecting the operation of the disclosed embodiments, configuration, and aspects.

A number of variations and modifications of the disclosure can be used. It would be possible to provide for some features of the disclosure without providing others. By way of illustration, any methodology or modality of cutting tissue may be employed as described herein to effect lead removal from an encased tissue growth.

The present disclosure, in various aspects, embodiments, and/or configurations, includes components, methods, processes, systems and/or apparatus substantially as depicted and described herein, including various aspects, embodiments, configurations embodiments, subcombinations, and/or subsets thereof. Those of skill in the art will understand how to make and use the disclosed aspects, embodiments, and/or configurations after understanding the present disclosure. The present disclosure, in various aspects, embodiments, and/or configurations, includes providing devices and processes in the absence of items not depicted and/or described herein or in various aspects, embodiments, and/or configurations hereof, including in the absence of such items as may have been used in previous devices or processes, e.g., for improving performance, achieving ease and/or reducing cost of implementation.

The foregoing discussion has been presented for purposes of illustration and description. The foregoing is not intended to limit the disclosure to the form or forms disclosed herein. In the foregoing Summary for example, various features of the disclosure are grouped together in one or more aspects, embodiments, and/or configurations for the purpose of streamlining the disclosure. The features of the aspects, embodiments, and/or configurations of the disclosure may be combined in alternate aspects, embodiments, and/or configurations other than those discussed above. This method of disclosure is not to be interpreted as reflecting an intention that the claims require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed aspect, embodiment, and/or configuration. Thus, the following claims are hereby incorporated into this Summary, with each claim standing on its own as a separate preferred embodiment of the disclosure.

Moreover, though the description has included description of one or more aspects, embodiments, and/or configurations and certain variations and modifications, other variations, combinations, and modifications are within the scope of the disclosure, e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure. It is intended to obtain rights which include alternative aspects, embodiments, and/or configurations to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter.

Claims

1. A tissue slitting device comprising: a shaft having a distal end, a longitudinal axis, and an inner lumen extending substantially through the shaft;an actuation guide comprising a track, wherein the track comprises a linear portion substantially parallel to the longitudinal axis of the shaft and a non-linear portion proximal to the linear portion;a cutting edge at the distal end of the shaft, wherein the cutting edge pivots on a pin that follows the track of the actuation guide; anda support element having a tapered outer surface and a lumen running therethrough, wherein the lumen of the support element is in communication with the inner lumen of the shaft.
2. The tissue slitting device of claim 1 wherein the cutting edge pivots away from the longitudinal axis of the shaft as the pin travels through the non-linear portion of the guide track.
3. The tissue slitting device of claim 1 wherein the cutting edge pivots away from the longitudinal axis of the shaft as the pin travels through the non-linear portion of the guide track.
4. The tissue slitting device of claim 1 further comprising a tissue slitting element comprising the cutting edge and a slitting orientation control feature disposed adjacent to the distal end of the tissue slitting device, wherein the slitting orientation control feature is configured to prevent rotation of the tissue slitting element into a vessel wall of a patient.
5. The tissue slitting device of claim 1 further comprising an actuation element and an end support device lock operatively connected to the actuation element that moves the end support device lock along the tapered outer surface of the support element and the movement of the end support device lock along the tapered outer surface of the support element reduces a diameter of the lumen running through the support element to provide a clamping force onto an object that is implanted in a patient.
6. The tissue slitting device of claim 1 wherein the support element is arranged as a collet separated into two or more end support elements that, when subjected to an actuation force, reduce an internal diameter of the lumen running through the support element.
7. The tissue slitting device of claim 1 wherein the cutting edge pivots away from a lead implanted in a patient with a lifting motion that produces tension on fibers of a tissue growth around the lead.
8. A tissue slitting device for removing an object implanted in a patient, the tissue slitting device comprising: a shaft for insertion into a lumen of the patient, the shaft having a distal end, a longitudinal axis, and an inner lumen extending substantially through the shaft;an actuation guide comprising a track, wherein the track comprises a linear portion substantially parallel to the longitudinal axis of the shaft and a non-linear portion proximal to the linear portion;a cutting edge at the distal end of the shaft comprising a pin, wherein the cutting edge pivots away from the longitudinal axis of the shaft as the pin travels through the non-linear portion of the guide track; anda support element having a tapered outer surface and a lumen running therethrough, wherein the lumen of the support element is in communication with the inner lumen of the shaft.
9. The tissue slitting device of claim 8 further comprising a tissue slitting element comprising the cutting edge and a slitting orientation control feature disposed adjacent to the distal end of the tissue slitting device, wherein the slitting orientation control feature is configured to prevent rotation of the tissue slitting element into a vessel wall of a patient.
10. The tissue slitting device of claim 9 further comprising an actuation element and an end support device lock operatively coupled to the actuation element.
11. The tissue slitting apparatus of claim 10, wherein the actuation element moves the end support device lock along the tapered outer surface of the support element, and wherein the movement of the end support device lock along the tapered outer surface of the support element reduces a diameter of the inner lumen to provide a clamping force onto the object implanted in the patient.
12. The tissue slitting apparatus of claim 8 wherein the support element is arranged as a collet separated into two or more end support elements that, when subjected to an actuation force, reduce an internal diameter of the lumen running through the support element.
13. The tissue slitting apparatus of claim 8 wherein the cutting edge pivots away from the object implanted in the patient with a lifting motion that produces tension on fibers of a tissue growth around the object.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 14/192,445, filed on Feb. 27, 2014, which claims the benefits of and priority, under 35 U.S.C. § 119(e), to U.S. Provisional Application Ser. No. 61/784,203, filed on Mar. 14, 2013, entitled “Distal End Supported Tissue Slitting Apparatus,” the entire disclosure of which is hereby incorporated herein by reference, in its entirety, for all that it teaches and for all purposes. This application is also related to U.S. patent application Ser. No. 13/828,231, filed on Mar. 14, 2013, entitled, “Tissue Slitting Methods and Systems”; Ser. No. 13/828,310, filed on Mar. 14, 2013, entitled, “Tissue Slitting Methods and Systems”; Ser. No. 13/828,383, filed on Mar. 14, 2013, entitled, “Tissue Slitting Methods and Systems”; Ser. No. 13/828,441, filed on Mar. 14, 2013, entitled, “Tissue Slitting Methods and Systems”; Ser. No. 13/828,638, filed on Mar. 14, 2013, entitled, “Lead Removal Sleeve” and Ser. No. 13/828,536, filed on Mar. 14, 2013, entitled, “Expandable Lead Jacket”. The entire disclosures of the applications listed above are hereby incorporated herein by reference, in their entirety, for all that they teach and for all purposes.

US Referenced Citations (772)

Number	Name	Date	Kind
1663761	Johnson	Mar 1928	A
3400708	Scheidt	Sep 1968	A
3521640	Carey	Jul 1970	A
3614953	Moss	Oct 1971	A
3805382	Benedict	Apr 1974	A
3831274	Horrocks	Aug 1974	A
3858577	Bass et al.	Jan 1975	A
4051596	Hofmann	Oct 1977	A
4203444	Bonnell et al.	May 1980	A
4246902	Martinez	Jan 1981	A
4274414	Johnson et al.	Jun 1981	A
4311138	Sugarman	Jan 1982	A
4471777	McCorkle, Jr.	Sep 1984	A
4517977	Frost	May 1985	A
4559927	Chin	Dec 1985	A
4566438	Liese et al.	Jan 1986	A
4567882	Heller	Feb 1986	A
4576162	McCorkle	Mar 1986	A
4582056	McCorkle et al.	Apr 1986	A
4598710	Kleinberg et al.	Jul 1986	A
4627436	Leckrone	Dec 1986	A
4641912	Goldenberg	Feb 1987	A
4646738	Trott	Mar 1987	A
4662869	Wright	May 1987	A
4674502	Imonti	Jun 1987	A
4718417	Kittrell	Jan 1988	A
4729763	Henrie	Mar 1988	A
4754755	Husted	Jul 1988	A
4767403	Hodge	Aug 1988	A
4844062	Wells	Jul 1989	A
4862886	Clarke	Sep 1989	A
4881550	Kothe	Nov 1989	A
4911148	Sosnowski et al.	Mar 1990	A
4943289	Goode et al.	Jul 1990	A
4988347	Goode et al.	Jan 1991	A
4997424	Little	Mar 1991	A
5011482	Goode et al.	Apr 1991	A
5013310	Goode et al.	May 1991	A
5030207	Mersch et al.	Jul 1991	A
5031634	Simon	Jul 1991	A
5041108	Fox et al.	Aug 1991	A
5114403	Clarke et al.	May 1992	A
5139494	Freiberg	Aug 1992	A
5139495	Daikuzono	Aug 1992	A
5148599	Purcell	Sep 1992	A
5152744	Krause et al.	Oct 1992	A
5186634	Thompson	Feb 1993	A
5201316	Pomeranz et al.	Apr 1993	A
5207683	Goode et al.	May 1993	A
5230334	Klopotek	Jul 1993	A
5250045	Bohley	Oct 1993	A
5263928	Trauthen et al.	Nov 1993	A
5275609	Pingleton et al.	Jan 1994	A
5290275	Kittrell et al.	Mar 1994	A
5290280	Daikuzono	Mar 1994	A
5290303	Pingleton et al.	Mar 1994	A
5353786	Wilk	Oct 1994	A
5358487	Miller	Oct 1994	A
5373840	Knighton	Dec 1994	A
5377683	Barken	Jan 1995	A
5383199	Laudenslager et al.	Jan 1995	A
5395328	Ockuly et al.	Mar 1995	A
5396902	Brennen et al.	Mar 1995	A
5423330	Lee	Jun 1995	A
5423806	Dale et al.	Jun 1995	A
5431674	Basile	Jul 1995	A
5456680	Taylor et al.	Oct 1995	A
5460182	Goodman et al.	Oct 1995	A
5466234	Loeb et al.	Nov 1995	A
5468238	Mersch	Nov 1995	A
5470330	Goldenberg et al.	Nov 1995	A
5484433	Taylor et al.	Jan 1996	A
5507751	Goode et al.	Apr 1996	A
5562694	Sauer et al.	Oct 1996	A
5569284	Young et al.	Oct 1996	A
5573531	Gregory	Nov 1996	A
5575797	Neubauer et al.	Nov 1996	A
5605539	Buelna et al.	Feb 1997	A
5620414	Campbell et al.	Apr 1997	A
5620451	Rosborough	Apr 1997	A
5632749	Goode et al.	May 1997	A
5651781	Grace	Jul 1997	A
5665051	Quick	Sep 1997	A
5667473	Finn et al.	Sep 1997	A
5682199	Lankford	Oct 1997	A
5697936	Sbipko et al.	Dec 1997	A
5700270	Peyser	Dec 1997	A
5707389	Louw et al.	Jan 1998	A
5718237	Haaga	Feb 1998	A
5725523	Mueller	Mar 1998	A
5735847	Gough et al.	Apr 1998	A
5746738	Cleary et al.	May 1998	A
5766164	Mueller et al.	Jun 1998	A
5782823	Mueller	Jul 1998	A
5807399	Laske et al.	Sep 1998	A
5814044	Hooven	Sep 1998	A
5823971	Robinson et al.	Oct 1998	A
5824026	Diaz	Oct 1998	A
5825958	Gollihar	Oct 1998	A
5863294	Alden	Jan 1999	A
5873886	Larsen et al.	Feb 1999	A
5879365	Whitfield et al.	Mar 1999	A
5893862	Pratt et al.	Apr 1999	A
5899915	Saadat	May 1999	A
5906611	Dodick et al.	May 1999	A
5910150	Saadat	Jun 1999	A
5916210	Winston	Jun 1999	A
5931848	Saadat	Aug 1999	A
5941893	Saadat	Aug 1999	A
5947958	Woodard et al.	Sep 1999	A
5951543	Brauer	Sep 1999	A
5951581	Saadat et al.	Sep 1999	A
5970982	Perkins	Oct 1999	A
5972012	Ream et al.	Oct 1999	A
5980515	Tu	Nov 1999	A
5980545	Pacala et al.	Nov 1999	A
5989243	Goldenberg	Nov 1999	A
6007512	Hooven	Dec 1999	A
6010476	Saadat	Jan 2000	A
6019756	Mueller et al.	Feb 2000	A
6022336	Zadno-Azizi et al.	Feb 2000	A
6027450	Brown et al.	Feb 2000	A
6027497	Daniel et al.	Feb 2000	A
6033402	Tu et al.	Mar 2000	A
6036685	Mueller	Mar 2000	A
6051008	Saadat et al.	Apr 2000	A
6066131	Mueller et al.	May 2000	A
6080175	Hogendijk	Jun 2000	A
6083237	Huitema et al.	Jul 2000	A
6099537	Sugai et al.	Aug 2000	A
6102926	Tartaglia et al.	Aug 2000	A
6117128	Gregory	Sep 2000	A
6120520	Saadat et al.	Sep 2000	A
6123718	Tu	Sep 2000	A
6126654	Giba et al.	Oct 2000	A
6129897	Daikuzono	Oct 2000	A
6136005	Goode et al.	Oct 2000	A
6139543	Esch et al.	Oct 2000	A
6152909	Bagaoisan et al.	Nov 2000	A
6152918	Padilla et al.	Nov 2000	A
6156049	Lovato et al.	Dec 2000	A
6159203	Sinofsky	Dec 2000	A
6159225	Makower	Dec 2000	A
6162214	Mueller et al.	Dec 2000	A
6165188	Saadat et al.	Dec 2000	A
6167315	Coe et al.	Dec 2000	A
6174307	Daniel et al.	Jan 2001	B1
6190352	Haarala et al.	Feb 2001	B1
6190353	Makower et al.	Feb 2001	B1
6193650	Ryan et al.	Feb 2001	B1
6203537	Adrian	Mar 2001	B1
6210400	Hebert et al.	Apr 2001	B1
6228052	Pohndorf	May 2001	B1
6228076	Winston et al.	May 2001	B1
6235044	Root et al.	May 2001	B1
6241692	Tu et al.	Jun 2001	B1
6245011	Dudda et al.	Jun 2001	B1
6251121	Saadat	Jun 2001	B1
6258083	Daniel et al.	Jul 2001	B1
6290668	Gregory et al.	Sep 2001	B1
6315774	Daniel et al.	Nov 2001	B1
6324434	Coe et al.	Nov 2001	B2
6368318	Visuri et al.	Apr 2002	B1
6395002	Ellman et al.	May 2002	B1
6398773	Bagaoisan et al.	Jun 2002	B1
6402771	Palmer et al.	Jun 2002	B1
6402781	Langberg et al.	Jun 2002	B1
6419674	Bowser et al.	Jul 2002	B1
6419684	Heisler et al.	Jul 2002	B1
6423051	Kaplan et al.	Jul 2002	B1
6428539	Baxter et al.	Aug 2002	B1
6428556	Chin	Aug 2002	B1
6432119	Saadat	Aug 2002	B1
6436054	Viola et al.	Aug 2002	B1
6436114	Novak et al.	Aug 2002	B1
6440125	Rentrop	Aug 2002	B1
6454741	Muni et al.	Sep 2002	B1
6454758	Thompson et al.	Sep 2002	B1
6461349	Elbrecht et al.	Oct 2002	B1
6478777	Honeck et al.	Nov 2002	B1
6485413	Boppart et al.	Nov 2002	B1
6485485	Winston et al.	Nov 2002	B1
6488636	Bryan et al.	Dec 2002	B2
6500182	Foster	Dec 2002	B2
6512959	Gomperz et al.	Jan 2003	B1
6527752	Bosley et al.	Mar 2003	B1
6537314	Langberg et al.	Mar 2003	B2
6554779	Viola et al.	Apr 2003	B2
6558382	Jahns et al.	May 2003	B2
6565583	Deaton et al.	May 2003	B1
6565588	Clement et al.	May 2003	B1
6569082	Chin	May 2003	B1
6575997	Palmer et al.	Jun 2003	B1
6592607	Palmer et al.	Jul 2003	B1
6595982	Sekino et al.	Jul 2003	B2
6599296	Gillick et al.	Jul 2003	B1
6602241	Makower et al.	Aug 2003	B2
6607547	Chin	Aug 2003	B1
6610046	Usami et al.	Aug 2003	B1
6610066	Dinger et al.	Aug 2003	B2
6613013	Haarala et al.	Sep 2003	B2
6620153	Mueller et al.	Sep 2003	B2
6620160	Lewis et al.	Sep 2003	B2
6620180	Bays et al.	Sep 2003	B1
6641590	Palmer et al.	Nov 2003	B1
6652480	Imran et al.	Nov 2003	B1
6652548	Evans et al.	Nov 2003	B2
6660021	Palmer et al.	Dec 2003	B1
6663621	Winston	Dec 2003	B1
6663626	Truckai et al.	Dec 2003	B2
6669685	Rizoiu et al.	Dec 2003	B1
6673090	Root et al.	Jan 2004	B2
6687548	Goode	Feb 2004	B2
6702813	Baxter et al.	Mar 2004	B1
6706018	Westlund et al.	Mar 2004	B2
6706052	Chin	Mar 2004	B1
6706065	Langberg et al.	Mar 2004	B2
6709456	Langberg et al.	Mar 2004	B2
6712773	Viola	Mar 2004	B1
6712826	Lui	Mar 2004	B2
6772014	Coe et al.	Aug 2004	B2
6802838	Loeb et al.	Oct 2004	B2
6805692	Muni et al.	Oct 2004	B2
6810882	Langberg et al.	Nov 2004	B2
6818001	Wulfman et al.	Nov 2004	B2
6855143	Davison	Feb 2005	B2
6858027	Redtenbacher et al.	Feb 2005	B2
6860860	Viola	Mar 2005	B2
6869431	Maguire et al.	Mar 2005	B2
6871085	Sommer	Mar 2005	B2
6884240	Dykes	Apr 2005	B1
6887238	Jahns et al.	May 2005	B2
6893450	Foster	May 2005	B2
6913612	Palmer et al.	Jul 2005	B2
6962585	Poleo et al.	Nov 2005	B2
6966906	Brown	Nov 2005	B2
6979290	Mourlas et al.	Dec 2005	B2
6979319	Manning et al.	Dec 2005	B2
6989028	Lashinski et al.	Jan 2006	B2
6999809	Currier et al.	Feb 2006	B2
7004956	Palmer et al.	Feb 2006	B2
7011682	Lashinski et al.	Mar 2006	B2
7029467	Currier et al.	Apr 2006	B2
7033335	Haarala et al.	Apr 2006	B2
7033344	Imran	Apr 2006	B2
7033357	Baxter et al.	Apr 2006	B2
7060061	Altshuler et al.	Jun 2006	B2
7063693	Guenst	Jun 2006	B2
7077856	Whitman	Jul 2006	B2
7092765	Geske et al.	Aug 2006	B2
7104983	Grasso et al.	Sep 2006	B2
7114642	Whitman	Oct 2006	B2
7117039	Manning et al.	Oct 2006	B2
7149587	Wardle et al.	Dec 2006	B2
7151965	Osypka	Dec 2006	B2
7189207	Viola	Mar 2007	B2
7191015	Lamson et al.	Mar 2007	B2
7192430	Truckai et al.	Mar 2007	B2
7204824	Moulis	Apr 2007	B2
7214180	Chin	May 2007	B2
7226459	Cesarini et al.	Jun 2007	B2
7238179	Brucker et al.	Jul 2007	B2
7238180	Mester et al.	Jul 2007	B2
7252641	Thompson et al.	Aug 2007	B2
7264587	Chin	Sep 2007	B2
7273478	Appling et al.	Sep 2007	B2
7276052	Kobayashi et al.	Oct 2007	B2
7288096	Chin	Oct 2007	B2
7296577	Lashinski et al.	Nov 2007	B2
7306588	Loeb et al.	Dec 2007	B2
7326226	Root et al.	Feb 2008	B2
7328071	Stehr et al.	Feb 2008	B1
7344546	Wulfman et al.	Mar 2008	B2
7357794	Makower et al.	Apr 2008	B2
7359756	Goode	Apr 2008	B2
7369901	Morgan et al.	May 2008	B1
7392095	Flynn et al.	Jun 2008	B2
7396354	Rychnovsky et al.	Jul 2008	B2
7398781	Chin	Jul 2008	B1
7449010	Hayase et al.	Nov 2008	B1
7462167	Kratz et al.	Dec 2008	B2
7485127	Nistal	Feb 2009	B2
7494484	Beck et al.	Feb 2009	B2
7507252	Lashinski et al.	Mar 2009	B2
7509169	Eigler et al.	Mar 2009	B2
7510524	Vayser et al.	Mar 2009	B2
7510576	Langberg et al.	Mar 2009	B2
7513877	Viola	Apr 2009	B2
7513892	Haarala et al.	Apr 2009	B1
7526342	Chin et al.	Apr 2009	B2
7537602	Whitman	May 2009	B2
7540865	Griffin et al.	Jun 2009	B2
7544197	Kelsch et al.	Jun 2009	B2
7559941	Zannis et al.	Jul 2009	B2
D600792	Eubanks et al.	Sep 2009	S
7591790	Pflueger	Sep 2009	B2
7597698	Chin	Oct 2009	B2
7606615	Makower et al.	Oct 2009	B2
7611474	Hibner et al.	Nov 2009	B2
7637904	Wingler et al.	Dec 2009	B2
7645286	Catanese et al.	Jan 2010	B2
7648466	Stephens et al.	Jan 2010	B2
7651503	Coe et al.	Jan 2010	B1
7651504	Goode et al.	Jan 2010	B2
D610259	Way et al.	Feb 2010	S
D611146	Way et al.	Mar 2010	S
7674272	Torrance et al.	Mar 2010	B2
7695485	Whitman et al.	Apr 2010	B2
7695512	Lashinski et al.	Apr 2010	B2
7697996	Manning et al.	Apr 2010	B2
7713231	Wulfman et al.	May 2010	B2
7713235	Torrance et al.	May 2010	B2
7713281	Leeflang et al.	May 2010	B2
7722549	Nakao	May 2010	B2
7740626	Takayama et al.	Jun 2010	B2
7743960	Whitman et al.	Jun 2010	B2
D619252	Way et al.	Jul 2010	S
D619253	Way et al.	Jul 2010	S
7758594	Lamson et al.	Jul 2010	B2
7758613	Whitman	Jul 2010	B2
D621939	Way et al.	Aug 2010	S
7766923	Catanese et al.	Aug 2010	B2
7780682	Catanese et al.	Aug 2010	B2
7780694	Palmer et al.	Aug 2010	B2
7794411	Ritchart et al.	Sep 2010	B2
7798813	Harrel	Sep 2010	B1
7801624	Flannery et al.	Sep 2010	B1
7803151	Whitman	Sep 2010	B2
7806835	Hibner et al.	Oct 2010	B2
7811281	Rentrop	Oct 2010	B1
7815655	Catanese et al.	Oct 2010	B2
7842009	Torrance et al.	Nov 2010	B2
7845538	Whitman	Dec 2010	B2
7858038	Andreyko et al.	Dec 2010	B2
7875018	Tockman et al.	Jan 2011	B2
7875049	Eversull et al.	Jan 2011	B2
7890186	Wardle et al.	Feb 2011	B2
7890192	Kelsch et al.	Feb 2011	B1
7896879	Solsberg et al.	Mar 2011	B2
7896891	Catanese et al.	Mar 2011	B2
7905889	Catanese et al.	Mar 2011	B2
7909836	McLean et al.	Mar 2011	B2
7914464	Burdorff et al.	Mar 2011	B2
7914542	Lamson et al.	Mar 2011	B2
D635671	Way et al.	Apr 2011	S
7918230	Whitman et al.	Apr 2011	B2
7918803	Ritchart et al.	Apr 2011	B2
7930040	Kelsch et al.	Apr 2011	B1
7935146	Langberg et al.	May 2011	B2
7938786	Ritchie et al.	May 2011	B2
7942830	Solsberg et al.	May 2011	B2
7951071	Whitman et al.	May 2011	B2
7951158	Catanese et al.	May 2011	B2
7963040	Shan et al.	Jun 2011	B2
7963433	Whitman et al.	Jun 2011	B2
7974710	Seifert	Jul 2011	B2
7981049	Ritchie et al.	Jul 2011	B2
7981050	Ritchart et al.	Jul 2011	B2
7981128	To et al.	Jul 2011	B2
7988726	Langberg et al.	Aug 2011	B2
7991258	Temelkuran et al.	Aug 2011	B2
7992758	Whitman et al.	Aug 2011	B2
7993350	Ventura et al.	Aug 2011	B2
7993351	Worley et al.	Aug 2011	B2
7993359	Atwell et al.	Aug 2011	B1
8007469	Duffy	Aug 2011	B2
8007488	Ravenscroft	Aug 2011	B2
8007503	Catanese et al.	Aug 2011	B2
8007506	To et al.	Aug 2011	B2
8016748	Mourlas et al.	Sep 2011	B2
8016844	Privitera et al.	Sep 2011	B2
8016855	Whitman et al.	Sep 2011	B2
8016858	Whitman	Sep 2011	B2
8021373	Whitman et al.	Sep 2011	B2
8025199	Whitman et al.	Sep 2011	B2
8043309	Catanese et al.	Oct 2011	B2
RE42959	Saadat et al.	Nov 2011	E
8052616	Andrisek et al.	Nov 2011	B2
8052659	Ravenscroft et al.	Nov 2011	B2
8056786	Whitman et al.	Nov 2011	B2
8056791	Whitman	Nov 2011	B2
8070762	Escudero et al.	Dec 2011	B2
8090430	Makower et al.	Jan 2012	B2
8097012	Kagarise	Jan 2012	B2
8100920	Gambale et al.	Jan 2012	B2
8118208	Whitman	Feb 2012	B2
8126570	Manning et al.	Feb 2012	B2
8128577	Viola	Mar 2012	B2
8128636	Lui et al.	Mar 2012	B2
8133214	Hayase et al.	Mar 2012	B2
8137377	Palmer et al.	Mar 2012	B2
8142442	Palmer et al.	Mar 2012	B2
8142446	Shan	Mar 2012	B2
RE43300	Saadat et al.	Apr 2012	E
8157815	Catanese et al.	Apr 2012	B2
8186559	Whitman	May 2012	B1
8187204	Miller et al.	May 2012	B2
8187268	Godara et al.	May 2012	B2
8192430	Goode et al.	Jun 2012	B2
8202229	Miller et al.	Jun 2012	B2
8206409	Privitera et al.	Jun 2012	B2
8211118	Catanese et al.	Jul 2012	B2
8216254	McLean et al.	Jul 2012	B2
8235916	Whiting et al.	Aug 2012	B2
8236016	To et al.	Aug 2012	B2
8239039	Zarembo et al.	Aug 2012	B2
8241272	Arnold et al.	Aug 2012	B2
8251916	Speeg et al.	Aug 2012	B2
8252015	Leeflang et al.	Aug 2012	B2
8257312	Duffy	Sep 2012	B2
8272554	Whitman et al.	Sep 2012	B2
8273078	Muenker	Sep 2012	B2
8295947	Lamson et al.	Oct 2012	B2
8303511	Eigler et al.	Nov 2012	B2
8323240	Wulfman et al.	Dec 2012	B2
8326437	Cully et al.	Dec 2012	B2
8333740	Shippert	Dec 2012	B2
8333776	Cheng et al.	Dec 2012	B2
8337516	Escudero et al.	Dec 2012	B2
8343167	Henson	Jan 2013	B2
8343187	Lamson et al.	Jan 2013	B2
8353899	Wells et al.	Jan 2013	B1
8361094	To et al.	Jan 2013	B2
8364280	Marnfeldt et al.	Jan 2013	B2
8372098	Tran	Feb 2013	B2
8394110	Catanese et al.	Mar 2013	B2
8394113	Wei et al.	Mar 2013	B2
8425535	McLean et al.	Apr 2013	B2
8632558	Chin et al.	Jan 2014	B2
20010005789	Root et al.	Jun 2001	A1
20010016717	Haarala et al.	Aug 2001	A1
20010025174	Daniel et al.	Sep 2001	A1
20010031981	Evans et al.	Oct 2001	A1
20010041899	Foster	Nov 2001	A1
20020002372	Jahns et al.	Jan 2002	A1
20020007204	Goode	Jan 2002	A1
20020010475	Lui	Jan 2002	A1
20020010487	Evans et al.	Jan 2002	A1
20020016628	Langberg et al.	Feb 2002	A1
20020026127	Balbierz	Feb 2002	A1
20020042610	Sliwa et al.	Apr 2002	A1
20020045811	Kittrell et al.	Apr 2002	A1
20020065543	Gomperz et al.	May 2002	A1
20020068954	Foster	Jun 2002	A1
20020077593	Perkins et al.	Jun 2002	A1
20020087151	Mody et al.	Jul 2002	A1
20020103477	Grasso et al.	Aug 2002	A1
20020103532	Langberg et al.	Aug 2002	A1
20020103533	Langberg et al.	Aug 2002	A1
20020123785	Zhang et al.	Sep 2002	A1
20020151961	Lashinski et al.	Oct 2002	A1
20020156346	Kamrava et al.	Oct 2002	A1
20020183735	Edwards et al.	Dec 2002	A1
20020188278	Tockman et al.	Dec 2002	A1
20030009146	Muni et al.	Jan 2003	A1
20030009157	Levine et al.	Jan 2003	A1
20030050630	Mody et al.	Mar 2003	A1
20030050631	Mody et al.	Mar 2003	A1
20030055444	Evans et al.	Mar 2003	A1
20030055445	Evans et al.	Mar 2003	A1
20030065312	Owa	Apr 2003	A1
20030065316	Levine et al.	Apr 2003	A1
20030069575	Chin et al.	Apr 2003	A1
20030073985	Mueller et al.	Apr 2003	A1
20030078562	Makower et al.	Apr 2003	A1
20030092995	Thompson	May 2003	A1
20030105451	Westlund et al.	Jun 2003	A1
20030125619	Manning et al.	Jul 2003	A1
20030144594	Gellman	Jul 2003	A1
20030167056	Jahns et al.	Sep 2003	A1
20030181935	Gardeski et al.	Sep 2003	A1
20030187460	Chin et al.	Oct 2003	A1
20030187461	Chin	Oct 2003	A1
20030199921	Palmer et al.	Oct 2003	A1
20030204202	Palmer et al.	Oct 2003	A1
20030208209	Gambale et al.	Nov 2003	A1
20030229323	Haarala et al.	Dec 2003	A1
20030229353	Cragg	Dec 2003	A1
20040006358	Wulfman et al.	Jan 2004	A1
20040010248	Appling et al.	Jan 2004	A1
20040015193	Lamson et al.	Jan 2004	A1
20040019359	Worley et al.	Jan 2004	A1
20040049208	Hill et al.	Mar 2004	A1
20040054368	Truckai et al.	Mar 2004	A1
20040054388	Osypka	Mar 2004	A1
20040059348	Geske et al.	Mar 2004	A1
20040059404	Bjorklund	Mar 2004	A1
20040064024	Sommer	Apr 2004	A1
20040068256	Rizoiu et al.	Apr 2004	A1
20040068288	Palmer et al.	Apr 2004	A1
20040093016	Root et al.	May 2004	A1
20040097788	Mourlas et al.	May 2004	A1
20040102804	Chin	May 2004	A1
20040102841	Langberg et al.	May 2004	A1
20040111101	Chin	Jun 2004	A1
20040116939	Goode	Jun 2004	A1
20040116992	Wardle et al.	Jun 2004	A1
20040133220	Lashinski et al.	Jul 2004	A1
20040138528	Richter et al.	Jul 2004	A1
20040138562	Makower et al.	Jul 2004	A1
20040138744	Lashinski et al.	Jul 2004	A1
20040143284	Chin	Jul 2004	A1
20040147911	Sinofsky	Jul 2004	A1
20040147912	Sinofsky	Jul 2004	A1
20040147913	Sinofsky	Jul 2004	A1
20040153096	Goode et al.	Aug 2004	A1
20040153098	Chin et al.	Aug 2004	A1
20040153146	Lashinski et al.	Aug 2004	A1
20040158236	Thyzel	Aug 2004	A1
20040172116	Seifert et al.	Sep 2004	A1
20040176840	Langberg et al.	Sep 2004	A1
20040181249	Torrance et al.	Sep 2004	A1
20040216748	Chin	Nov 2004	A1
20040220519	Wulfman et al.	Nov 2004	A1
20040225280	Horrigan	Nov 2004	A1
20040230212	Wulfman	Nov 2004	A1
20040230213	Wulfman et al.	Nov 2004	A1
20040235611	Nistal	Nov 2004	A1
20040236312	Nistal et al.	Nov 2004	A1
20040236397	Coe et al.	Nov 2004	A1
20040243123	Grasso et al.	Dec 2004	A1
20040243162	Wulfman et al.	Dec 2004	A1
20040254534	Bjorkman et al.	Dec 2004	A1
20040260322	Rudko et al.	Dec 2004	A1
20040267276	Camino et al.	Dec 2004	A1
20040267304	Zannis et al.	Dec 2004	A1
20050004644	Kelsch et al.	Jan 2005	A1
20050025798	Moulis	Feb 2005	A1
20050027199	Clarke	Feb 2005	A1
20050027337	Rudko et al.	Feb 2005	A1
20050038419	Arnold et al.	Feb 2005	A9
20050060030	Lashinski et al.	Mar 2005	A1
20050065561	Manning et al.	Mar 2005	A1
20050090748	Makower et al.	Apr 2005	A1
20050096643	Brucker	May 2005	A1
20050096740	Langberg et al.	May 2005	A1
20050131399	Loeb et al.	Jun 2005	A1
20050149104	Leeflang et al.	Jul 2005	A1
20050149105	Leeflang et al.	Jul 2005	A1
20050165288	Rioux et al.	Jul 2005	A1
20050197623	Leeflang et al.	Sep 2005	A1
20050222607	Palmer et al.	Oct 2005	A1
20050228402	Hofmann	Oct 2005	A1
20050228452	Mourlas et al.	Oct 2005	A1
20050251116	Steinke et al.	Nov 2005	A1
20050259942	Temelkuran et al.	Nov 2005	A1
20050273090	Nieman et al.	Dec 2005	A1
20050283143	Rizoiu	Dec 2005	A1
20050288596	Eigler et al.	Dec 2005	A1
20050288604	Eigler et al.	Dec 2005	A1
20050288654	Nieman et al.	Dec 2005	A1
20050288722	Eigler et al.	Dec 2005	A1
20060004317	Mauge et al.	Jan 2006	A1
20060052660	Chin	Mar 2006	A1
20060084839	Mourlas et al.	Apr 2006	A1
20060100663	Palmer et al.	May 2006	A1
20060116746	Chin	Jun 2006	A1
20060116757	Lashinski et al.	Jun 2006	A1
20060167417	Kratz et al.	Jul 2006	A1
20060173440	Lamson et al.	Aug 2006	A1
20060217755	Eversull et al.	Sep 2006	A1
20060229490	Chin	Oct 2006	A1
20060235431	Goode et al.	Oct 2006	A1
20060247751	Seifert	Nov 2006	A1
20060253179	Goode et al.	Nov 2006	A1
20060265042	Catanese et al.	Nov 2006	A1
20060276871	Lamson et al.	Dec 2006	A1
20060287574	Chin	Dec 2006	A1
20070015964	Eversull et al.	Jan 2007	A1
20070016130	Leeflang et al.	Jan 2007	A1
20070021812	Manning et al.	Jan 2007	A1
20070049929	Catanese et al.	Mar 2007	A1
20070050003	Zarembo et al.	Mar 2007	A1
20070078500	Ryan	Apr 2007	A1
20070083217	Eversull et al.	Apr 2007	A1
20070100410	Lamson et al.	May 2007	A1
20070106328	Wardle et al.	May 2007	A1
20070129710	Rudko et al.	Jun 2007	A1
20070142846	Catanese et al.	Jun 2007	A1
20070197861	Reiley et al.	Aug 2007	A1
20070198020	Reiley et al.	Aug 2007	A1
20070232981	Ravenscroft et al.	Oct 2007	A1
20070276412	Catanese et al.	Nov 2007	A1
20070293853	Truckal et al.	Dec 2007	A1
20080004643	To et al.	Jan 2008	A1
20080004644	To et al.	Jan 2008	A1
20080004645	To et al.	Jan 2008	A1
20080004646	To et al.	Jan 2008	A1
20080004647	To et al.	Jan 2008	A1
20080015625	Ventura et al.	Jan 2008	A1
20080021484	Catanese et al.	Jan 2008	A1
20080021485	Catanese et al.	Jan 2008	A1
20080033232	Catanese et al.	Feb 2008	A1
20080033456	Catanese et al.	Feb 2008	A1
20080033458	McLean et al.	Feb 2008	A1
20080033488	Catanese et al.	Feb 2008	A1
20080039833	Catanese et al.	Feb 2008	A1
20080039872	Catanese et al.	Feb 2008	A1
20080039874	Catanese et al.	Feb 2008	A1
20080039875	Catanese et al.	Feb 2008	A1
20080039876	Catanese et al.	Feb 2008	A1
20080039889	Lamson et al.	Feb 2008	A1
20080039893	McLean et al.	Feb 2008	A1
20080039894	Catanese et al.	Feb 2008	A1
20080045986	To et al.	Feb 2008	A1
20080051756	Makower et al.	Feb 2008	A1
20080058759	Makower et al.	Mar 2008	A1
20080071341	Goode et al.	Mar 2008	A1
20080071342	Goode et al.	Mar 2008	A1
20080097378	Zuckerman	Apr 2008	A1
20080097426	Root et al.	Apr 2008	A1
20080103439	Torrance et al.	May 2008	A1
20080103446	Torrance et al.	May 2008	A1
20080103516	Wulfman et al.	May 2008	A1
20080125634	Ryan et al.	May 2008	A1
20080125748	Patel	May 2008	A1
20080147061	Goode et al.	Jun 2008	A1
20080154293	Taylor	Jun 2008	A1
20080154296	Taylor et al.	Jun 2008	A1
20080183163	Lampropoulos et al.	Jul 2008	A1
20080194969	Werahera	Aug 2008	A1
20080195128	Orbay	Aug 2008	A1
20080208105	Zelickson et al.	Aug 2008	A1
20080221560	Arai et al.	Sep 2008	A1
20080228208	Wulfman et al.	Sep 2008	A1
20080249516	Muenker	Oct 2008	A1
20080262516	Gambale et al.	Oct 2008	A1
20080275497	Palmer et al.	Nov 2008	A1
20080275498	Palmer et al.	Nov 2008	A1
20080281308	Neuberger et al.	Nov 2008	A1
20080287888	Ravenscroft	Nov 2008	A1
20080306333	Chin	Dec 2008	A1
20090012510	Bertolero et al.	Jan 2009	A1
20090018523	Lamson et al.	Jan 2009	A1
20090018553	McLean et al.	Jan 2009	A1
20090034927	Temelkuran et al.	Feb 2009	A1
20090036871	Hayase et al.	Feb 2009	A1
20090054918	Henson	Feb 2009	A1
20090060977	Lamson et al.	Mar 2009	A1
20090071012	Shan et al.	Mar 2009	A1
20090076522	Shan	Mar 2009	A1
20090131907	Chin et al.	May 2009	A1
20090157045	Haarala et al.	Jun 2009	A1
20090182313	Auld	Jul 2009	A1
20090187196	Vetter	Jul 2009	A1
20090192439	Lamson et al.	Jul 2009	A1
20090198098	Okada	Aug 2009	A1
20090204128	Lamson et al.	Aug 2009	A1
20090221994	Neuberger et al.	Sep 2009	A1
20090222025	Catanese et al.	Sep 2009	A1
20090227999	Willis et al.	Sep 2009	A1
20090234378	Escudero et al.	Sep 2009	A1
20090319015	Horn-Wyffels	Dec 2009	A1
20100004606	Hansen et al.	Jan 2010	A1
20100016836	Makower et al.	Jan 2010	A1
20100030154	Duffy	Feb 2010	A1
20100030161	Duffy	Feb 2010	A1
20100030262	McLean et al.	Feb 2010	A1
20100030263	Cheng et al.	Feb 2010	A1
20100049225	To et al.	Feb 2010	A1
20100063488	Fischer et al.	Mar 2010	A1
20100125253	Olson et al.	May 2010	A1
20100137873	Grady et al.	Jun 2010	A1
20100160952	Leeflang et al.	Jun 2010	A1
20100191165	Appling et al.	Jul 2010	A1
20100198194	Manning et al.	Aug 2010	A1
20100198229	Olomutzki et al.	Aug 2010	A1
20100217277	Truong	Aug 2010	A1
20100222737	Arnold et al.	Sep 2010	A1
20100222787	Goode et al.	Sep 2010	A1
20100240951	Catanese et al.	Sep 2010	A1
20100256616	Katoh et al.	Oct 2010	A1
20100268175	Lunsford	Oct 2010	A1
20100280496	Shippert	Nov 2010	A1
20100324472	Wulfman	Dec 2010	A1
20100331793	Tulleken	Dec 2010	A1
20110004238	Palmer et al.	Jan 2011	A1
20110009957	Langberg et al.	Jan 2011	A1
20110022057	Eigler et al.	Jan 2011	A1
20110028959	Chasan	Feb 2011	A1
20110034790	Mourlas et al.	Feb 2011	A1
20110040238	Wulfman et al.	Feb 2011	A1
20110040312	Lamson et al.	Feb 2011	A1
20110040315	To et al.	Feb 2011	A1
20110040326	Wei et al.	Feb 2011	A1
20110046648	Johnston et al.	Feb 2011	A1
20110054493	McLean et al.	Mar 2011	A1
20110060349	Cheng et al.	Mar 2011	A1
20110071440	Torrance et al.	Mar 2011	A1
20110105947	Fritscher-Ravens et al.	May 2011	A1
20110106004	Eubanks et al.	May 2011	A1
20110106099	Duffy et al.	May 2011	A1
20110112548	Fifer et al.	May 2011	A1
20110112562	Torrance	May 2011	A1
20110112563	To et al.	May 2011	A1
20110112564	Wolf	May 2011	A1
20110118660	Torrance et al.	May 2011	A1
20110144423	Tong et al.	Jun 2011	A1
20110144425	Catanese et al.	Jun 2011	A1
20110151463	Wulfman	Jun 2011	A1
20110152607	Catanese et al.	Jun 2011	A1
20110152906	Escudero et al.	Jun 2011	A1
20110152907	Escudero et al.	Jun 2011	A1
20110160747	McLean et al.	Jun 2011	A1
20110160748	Catanese et al.	Jun 2011	A1
20110166564	Merrick et al.	Jul 2011	A1
20110178543	Chin et al.	Jul 2011	A1
20110190758	Lamson et al.	Aug 2011	A1
20110196298	Anderson et al.	Aug 2011	A1
20110196355	Mitchell et al.	Aug 2011	A1
20110196357	Srinivasan	Aug 2011	A1
20110208207	Bowe et al.	Aug 2011	A1
20110213398	Chin et al.	Sep 2011	A1
20110218528	Ogata et al.	Sep 2011	A1
20110238078	Goode et al.	Sep 2011	A1
20110238102	Gutfinger et al.	Sep 2011	A1
20110245751	Hofmann	Oct 2011	A1
20110257592	Ventura et al.	Oct 2011	A1
20110270169	Gardeski et al.	Nov 2011	A1
20110270170	Gardeski et al.	Nov 2011	A1
20110270289	To et al.	Nov 2011	A1
20110300010	Jarnagin et al.	Dec 2011	A1
20110301417	Mourlas et al.	Dec 2011	A1
20110301626	To et al.	Dec 2011	A1
20120035590	Whiting et al.	Feb 2012	A1
20120041422	Whiting et al.	Feb 2012	A1
20120053564	Ravenscroft	Mar 2012	A1
20120065466	Slater	Mar 2012	A1
20120065659	To	Mar 2012	A1
20120083810	Escudero et al.	Apr 2012	A1
20120083826	Chao et al.	Apr 2012	A1
20120095447	Fojtik	Apr 2012	A1
20120095479	Bowe et al.	Apr 2012	A1
20120097174	Spotnitz et al.	Apr 2012	A1
20120123411	Ibrahim et al.	May 2012	A1
20120136341	Appling et al.	May 2012	A1
20120165827	Khairkhahan et al.	Jun 2012	A1
20120165861	Palmer et al.	Jun 2012	A1
20120191015	Zannis et al.	Jul 2012	A1
20120209173	Hayase et al.	Aug 2012	A1
20120215305	Le et al.	Aug 2012	A1
20120239008	Fojtik	Sep 2012	A1
20120245600	McLean et al.	Sep 2012	A1
20120253229	Cage	Oct 2012	A1
20120265183	Tulleken et al.	Oct 2012	A1
20120323252	Booker	Dec 2012	A1
20120323253	Garai et al.	Dec 2012	A1
20120330292	Shadduck et al.	Dec 2012	A1
20130006228	Johnson et al.	Jan 2013	A1
20130035676	Mitchell et al.	Feb 2013	A1
20130085486	Boutoussov et al.	Apr 2013	A1
20130096582	Cheng et al.	Apr 2013	A1
20130103047	Steingisser et al.	Apr 2013	A1
20140031800	Ben Oren et al.	Jan 2014	A1
20140081252	Bowe et al.	Mar 2014	A1
20140081289	Fiser	Mar 2014	A1
20140081303	Bowe et al.	Mar 2014	A1
20140081304	Bowe et al.	Mar 2014	A1
20140081306	Bowe et al.	Mar 2014	A1
20140081367	Hendrick et al.	Mar 2014	A1
20140275982	Hendrick et al.	Sep 2014	A1
20140276682	Hendrick et al.	Sep 2014	A1
20140276683	Hendrick et al.	Sep 2014	A1
20140276694	Hendrick et al.	Sep 2014	A1
20140276695	Burton	Sep 2014	A1
20140276696	Schneider	Sep 2014	A1
20140276920	Hendrick et al.	Sep 2014	A1
20140277037	Grace et al.	Sep 2014	A1
20160022303	Fiser	Jan 2016	A1
20160338727	Bowe	Nov 2016	A1
20170325835	Bowe	Nov 2017	A1
20170340346	Hendrick	Nov 2017	A1

Foreign Referenced Citations (32)

Number	Date	Country
4038773	Jun 1992	DE
H05506382	Sep 1993	JP
2004516073	Jun 2004	JP
1991006271	May 1991	WO
1991017711	Nov 1991	WO
1993018818	Sep 1993	WO
1995033513	Dec 1995	WO
1999007295	Feb 1999	WO
1999049937	Oct 1999	WO
1999058066	Nov 1999	WO
2001076680	Oct 2001	WO
2002049690	May 2003	WO
2004049956	Jun 2004	WO
2004080345	Sep 2004	WO
2004080507	Sep 2004	WO
2006007410	Jan 2006	WO
2008005888	Jan 2008	WO
2008005891	Jan 2008	WO
2008042987	Apr 2008	WO
2009005779	Jan 2009	WO
2009054968	Apr 2009	WO
2009065082	May 2009	WO
2009126309	Oct 2009	WO
2011003113	Jan 2011	WO
2011084863	Jul 2011	WO
2011133941	Oct 2011	WO
2011162595	Dec 2011	WO
2012009697	Apr 2012	WO
2012098335	Jul 2012	WO
2012114333	Aug 2012	WO
2012177117	Dec 2012	WO
2013036588	Mar 2013	WO

Non-Patent Literature Citations (33)

Entry
Extended European Search Report issued in EP Application No. 13836886.5, dated Apr. 7, 2016, 6 pages.
Papaioannou, T., et al. Excimer Laser (308 nm) Recanalisation of In-Stent Restenosis: Thermal Considerations, Lasers Med Sci., 16(2):90-100, 2001. [Abstract Only].
St. Luke's Roosevelt Hospital Center. Laser Lead Extraction. Arrhythmia News, 11(2), 3 pages, 2006.
Department of Health and Ageing in Australian Government, “Horizon Scanning Technology Prioritising: Laser Extraction Systems.” 2010. 15 pages.
International Preliminary Examination Report issued in PCT/US2013/059434, completed Mar. 26, 2015, 11 pages.
International Preliminary Examination Report issued in PCT/US2013/059448, completed Mar. 26, 2015, 9 pages.
International Search Report and Written Opinion issued in PCT/US2013/059448, dated Dec. 16, 2013, 12 pages.
Kennergren et al. “Laser-Assisted Lead Extraction: the European Experience.” Europace. 2007, vol. 9, No. 8. 6 pages.
Wilkoff, Bruce et al. “Pacemaker Lead Extraction with the Laser Sheath: Results of the Pacing Lead Extraction with the Excimer Sheath (Plexes) Trial.” Journal of the American College of Cardiology, 1999. vol. 33, No. 6. 8 pages.
Decision to Grant for European Patent Application No. 07255018.9, dated Aug. 8, 2013, 2 pages.
Extended European Search Report for European Application No. 07255018.9, dated Nov. 12, 2010.
Final Action for U.S. Appl. No. 11/615,005, dated Nov. 9, 2009, 10 pages.
Final Action for U.S. Appl. No. 11/615,005, dated Nov. 21, 2013, 20 pages.
Final Action for U.S. Appl. No. 11/615,006 dated Oct. 26, 2009, 9 pages.
Intent to Grant for European Patent Application No. 07255018.9, dated Nov. 29, 2012, 7 pages.
International Search Report and Written Opinion for International Patent Application No. PCT/US2013/059434, dated Dec. 13, 2013, 14 pages.
Notice of Allowance for European Patent Application No. 07255018.9, dated Jul. 26, 2012, 47 pages.
Notice of Allowance for Japan Patent Application No. 2007-333273, dated Jan. 16, 2014, 3 pages.
Official Action for European Application No. 07255019.7, dated Jul. 21, 2010 4 pages.
Official Action for European Patent Application No. 07255018.9, dated Jul. 19, 2011, 3 pages.
Official Action for U.S. Appl. No. 11/615,005, dated Apr. 16, 2009, 13 pages.
Official Action for U.S. Appl. No. 11/615,005, dated Feb. 11, 2011, 12 pages.
Official Action for U.S. Appl. No. 11/615,005, dated Jul. 21, 2010, 10 pages.
Official Action for U.S. Appl. No. 11/615,005, dated Mar. 14, 2013, 16 pages.
Official Action for U.S. Appl. No. 13/800,728, dated Jan. 16, 2014, 14 pages.
Official Action for U.S. Appl. No. 11/615,006 dated Apr. 24, 2009, 7 pages.
Official Action for U.S. Appl. No. 11/615,006 dated Feb. 17, 2010, 8 pages.
Official Action for U.S. Appl. No. 11/615,006 dated Jul. 20, 2010, 9 pages.
Official Action for U.S. Appl. No. 11/615,006 dated Mar. 14, 2013, 16 pages.
Official Action for U.S. Appl. No. 11/615,006 dated Nov. 22, 2013, 16 pages.
Official Action with English translation for Japan Patent Application No. 2007-333173, dated Apr. 30, 2013, 5 pages.
Official Action with English translation for Japan Patent Application No. 2007-333173, dated Aug. 13, 2012, 7 pages.
Extended European Search Report issued in EP application 13837908, dated May 5, 2016, 6 pages.

Related Publications (1)

	Number	Date	Country
	20210068859 A1	Mar 2021	US

Provisional Applications (1)

	Number	Date	Country
	61784203	Mar 2013	US

Continuations (1)

	Number	Date	Country
Parent	14192445	Feb 2014	US
Child	16950196		US

Distal end supported tissue slitting apparatus

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

CPC

Field of Search

CPC

International Classifications

Disclaimer

Term Extension

Abstract